TITLE

Using synthetic controls to estimate the population-level effects of Ontario's recently implemented overdose prevention sites and consumption and treatment services

Dimitra Panagiotoglou[1], PhD; Jihoon Lim[1], MS

[1]Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

Corresponding Author:

Dimitra Panagiotoglou
Department of Epidemiology, Biostatistics and Occupational Health
School of Population and Global Health
McGill University
2001 McGill College Avenue Suite 1200
Montreal, Quebec H3A 1G1
Email: dimitra.panagiotoglou@mcgill.ca
Telephone: +1 514 398 8451

ABSTRACT (287 / 300 words)

Background: Between 2017 and 2020, Ontario implemented overdose prevention sites (OPS) and consumption and treatment services (CTS) in nine of its 34 public health units (PHU). We tested for the effect of booth-hours (spaces within OPS/CTSs for supervised consumption) on opioid-related health service use and mortality rates at the provincial- (aggregate) and PHU-level.

Methods: We used monthly rates of all opioid-related emergency department (ED) visits, hospitalizations, and deaths between January 2015 and March 2021 as our three outcomes. For each PHU that implemented OPS/CTSs, we created a synthetic control as a weighted combination of unexposed PHUs. Our exposure was the time-varying rate of booth-hours provided. We estimated the population-level effects of the intervention on each outcome per treated/synthetic-control pair using controlled interrupted time series with segmented regression; and tested for the aggregate effect using a multiple baseline approach. We adjusted for time-varying provision of prescription opioids for pain management, opioid agonist treatment (OAT), and naloxone kits; and corrected for seasonality and autocorrelation. All rates were per 100,000 population. For sensitivity analysis, we restricted the post-implementation period to before COVID-19 public health measures were implemented (March 2020).

Results: Our aggregate analyses found no effect per booth-hour on ED visit (0.00, 95% CI: -0.01, 0.01; p-value=0.6684), hospitalization (0.00, 95% CI: 0.00, 0.00; p-value=0.9710) or deaths (0.00, 95% CI: 0.00, 0.00; p-value=0.2466). However, OAT reduced ED visits (-0.20, 95% CI: -0.35, -0.05; p-value=0.0103) and deaths (-0.04, 95% CI: -0.05, -0.03; p-value=<0.0001). Conversely, prescription opioids for pain management modestly increased deaths (0.0008, 95% CI: 0.0002, 0.0015; p-value=0.0157) per 100,000 population, respectively. Except for a few treated PHU/synthetic control pairs, disaggregate results were congruent with overall findings.

Conclusion: Booth-hours had no population-level effect on opioid-related overdose ED visit, hospitalization, or death rates.

Key words: overdose prevention sites, consumption and treatment services, harm reduction interventions, interrupted time series, synthetic controls

INTRODUCTION

Between January 2016 and June 2021, there were 24,626 opioid-related overdose deaths, and at least 27,604 opioid poisoning hospitalizations in Canada (Special Advisory Committee on the Epidemic of Opioid Overdoses, 2022). Although British Columbia is Canada's hardest hit province, Ontario is a close second in opioid-related disease burden and health service use. Over a ten-year period (2007-2016, inclusive), Ontario's emergency department (ED) visits increased 50% to 55.3 per 100,000 population (Tam, 2018) and hospitalizations rose 12% to 14.8 per 100,000 population (Canadian Institute for Health Information, 2018). For the first time in decades, male life expectancy at birth decreased as a consequence of high opioid-related mortality observed in younger adults (25 – 44 years of age) (Statistics Canada, 2020).

Overdose prevention sites (OPS) and consumption and treatment services (CTS) are among a suite of harm reduction interventions (e.g., supervised injection facilities, needle and syringe programs, naloxone distribution programs, drug checking services, and opioid agonist treatment (OAT)) increasingly offered across Canada to mitigate the negative physical and social consequences of illicit drug use (Strike & Watson, 2019). Historically unsanctioned, OPSs are temporary sites providing nimble, grassroots, peer-managed responses to the neglected needs of people who use illicit substances. Aside from providing critical overdose reversal services, OPSs offer overdose prevention education, Take Home Naloxone training and distribution, access to drug use equipment, and safe disposal of used equipment (BC Centre for Disease Control, 2019; Ministry of Health and Long-Term Care, 2018a). As of 2017, OPSs no longer require federal government (Health Canada) exemption under section 56.1 of the Controlled Drugs and Substances Act during public health emergencies. Conversely, CTSs (elsewhere known as supervised consumption sites) have Health Canada approval and must have a designated health professional (e.g., nurse) on-site. Aside from the harm reduction services available at OPSs, CTSs must also offer or provide a defined, proximal pathway to addictions treatment services (i.e., OAT, detox, residential or community treatment), primary care, mental health, and housing or social assistance programs (Ministry of Health and Long-Term Care, 2018a). Notably, CTSs do not offer supervised inhalation services.

While some authors have concluded that supervised consumption sites (namely, safe injection facilities) reduce mortality and health service use, they remain politically controversial (Potier C, Laprévote V, Dubois-Arber F, Cottencin O, & Rolland B, 2014). Much of the available evidence is from the concentrated drug use epidemics of Vancouver's Downtown Eastside and Sydney's 'red light' district and specific to injection drug use (Kennedy, Hayashi, Milloy, Wood, & Kerr, 2019; Potier C et al., 2014). The effects of supervised consumption site variants such as OPSs and CTSs remain unclear, particularly in contexts where the population is geographically diffuse, services are not restricted to people who inject drugs, and mobile rather than fixed sites operate. Further, most studies fail to distinguish the effects of supervised consumption sites from other harm reduction interventions also available (Caulkins, Pardo, & Kilmer, 2019). Our aim is to

estimate the population-level effects of Ontario's OPS/CTSs implemented between 2017 and 2020 (inclusive) on opioid-related ED visit, hospitalization, and death rates, while controlling for other time-varying interventions including rates of prescription opioids for pain management and opioid agonist treatment (separately) and naloxone kits distributed. Based on results from a similar analysis we conducted using the British Columbia Centre for Disease Control's Overdose Cohort data, we hypothesize that OPS/CTSs had no effects on health service use and death rates once we control for co-occurring time-varying interventions (Panagiotoglou, 2022). Results from this study are pertinent to other communities with population demographics and needs different from Vancouver's well studied Downtown Eastside.

METHODS

Study Design

We conducted a retrospective, ecological study that uses variations in the provision of OPS/CTS across Ontario's public health units (PHU) to examine population-level health outcomes.

Setting

Ontario is Canada's most populous province with approximately 14.75 million residents (Government of Ontario, 2020), 97% of whom are covered by the provincial health insurance program (Izenberg, Iroanyah, & Thompson, 2018). Within the province, health promotion and disease prevention are administered by PHUs, which have mutually exclusive and exhaustive health boundaries. The 34 PHUs range from 33,166 residents in Timiskaming, the province's most sparsely populated health unit, to 3,094,237 for its densest, most populated urban unit, Toronto (Government of Ontario, 2020).

Beginning in 2016, several provincial and federal harm reduction interventions were implemented to stem the rising rate of opioid-related overdose deaths. In June 2016, the Ontario Naloxone Program for Pharmacies (ONPP) began offering naloxone injection kits at no charge to individuals at risk of opioid-related overdose or persons in a position to assist someone at risk of an overdose, while select community-based organizations continued to dispense naloxone to at-risk clients, friends and family through a program that first began in 2013 (Canadian Centre on Substance Abuse & Canadian Community Epidemiology Network on Drug Use, 2016; Canadian Pharmacists Association, 2017). Shortly thereafter, naloxone kits transitioned from an injectable formulation to nasal spray (January 2017), the federal government's Good Samaritan Drug Overdose Act became law (May 2017) (Government of Canada, 2018), and PHUs began sub-distributing naloxone kits to community-based organizations much more widely through the Ontario Naloxone Program (ONP, September 2017) (Gogolishvili & Wasdell, 2020). Although some cities began operating unsanctioned sites earlier in the year, Health Canada issued an exemption to Ontario to establish legally sanctioned temporary OPSs on December 7, 2017 (Ontario Ministry of Health & Ontario Ministry of Long-Term Care, 2018). Beginning October 2018, the government of Ontario enforced a list of required services and metrics

that needed to be met for continued approval and financial support of CTSs (Ministry of Health and Long-Term Care, 2018a) and applied a cap to the number of sites allowed, ostensibly restricting provision of sites to larger cities (Russell, Imtiaz, Ali, Elton-Marshall, & Rehm, 2020).

Between June 2017 and December 2020, nine of the 34 provincial PHUs began operating at least one OPS/CTSs. These were in Toronto (n=9, 2 additional shelter-hotel sites), Ottawa (n=5), and one each in Hamilton, Kingston, London, Niagara, Thunder Bay, Guelph, and Waterloo (Pivot Legal Society, 2020) (Supplementary Table 1 for implementation dates, hours of operation, and capacity).

We excluded two PHUs that merged during the study period (Southwestern and Huron-Perth) with a combined population of approximately 336,000 (2.3%) from subsequent analysis owing to the incomplete demographic data available and differences between public health units' and Statistics Canada's jurisdictional boundaries.

Data collection and measures

We used monthly counts of all opioid-related ED visits, acute care hospitalizations, and deaths between January 2014 and March 2021, reported at the PHU-level in Ontario's publicly accessible Interactive Opioid Tool (Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2020). Across the 32 PHUs included in the study, there were 53,806 ED visits, 13,734 hospitalizations and 9,377 mortalities for opioid-related overdose events during this time.

Opioid overdose related emergency department visits, acute care hospitalizations, and deaths:

The Interactive Opioid Tool includes all opioid-related ED visits and acute care hospitalizations as captured in the province-wide National Ambulatory Care Reporting System (NACRS) and Discharge Abstract Database (DAD), respectively. We included all fatal events where accidental opioid poisoning from codeine, fentanyl (including carfentanil and other fentanyl analogues), heroin, hydrocodone, hydromorphone, methadone, morphine, or oxycodone was considered a contributing cause of death according to the Office of the Chief Coroner are also included. More than one opioid can be present at time of death, and presence of a drug does not necessarily indicate that it contributed to death. We converted event counts to rates per 100,000 to enable comparability between PHUs using the Ontario Ministry of Health and Long-Term Care's IntelliHealth population level estimates (2003-2016) and population projections (2017 – 2021) also available on the Interactive Opioid Tool.

Other data

We supplemented the PHU-level overdose event data with population-level annual demographics (percent of the population without a high school diploma, immigrant, and visible minority; median household income);

age- and sex-standardized rates of alcohol-related emergency department visits and hospitalizations; and monthly rates per 100,000 of concomitant interventions: persons receiving opioid prescriptions (for pain management and OAT, separately), and naloxone kits distributed. Finally, we created a measure of OPS/CTS intervention 'intensity' as the sum of the product of individual booth-spaces and hours available for supervised consumption of illicit substances across sites and standardized it to booth-hours per 100,000 population. For full definitions, data sources, and methods, please see supplementary material.

Ethics approval

This study was exempt from ethics review by McGill University's Institutional Review Board.

Statistical analysis

We used controlled interrupted time series with segmented regression to test the effects of OPS/CTS booth-hours on opioid-related ED visits, hospitalizations, or deaths (Bernal JL, Cummins S, & Gasparrini A, 2017). Interrupted time series analysis is a quasi-experimental study design that estimates population-level effects of health service or policy interventions before and after implementation in contexts where randomized controlled trials are not feasible or ethical (Cook TD & DT, 1979; Zhang F, Wagner AK, & Ross-Degnan D, 2011). The advantage of including a well-chosen control as the counterfactual is that selection bias and within-group characteristics that change slowly over time, secular changes, random fluctuations from one time point to the next and regression to the mean are also controlled (Lopez Bernal, Cummins, & Gasparrini, 2018).

Treated groups included all PHUs that implemented at least one OPS/CTS during the study period. Synthetic controls were derived for each treated PHU per outcome from a donor pool of exclusively never-treated PHUs (Baker, Larcker, & Wang, 2021) using Abadie et al.'s data-driven method and the Synth package with its extensions in R (Abadie, Diamond, & Hainmueller, 2011; Castanho Silva & DeWitt, 2020; Degli Esposti et al., 2020). The pre-intervention period was restricted to two years to optimize prediction of the treatment group by the comparison group (Bilinski, 2021).

We fitted the following linear regression model for intervention status *j* (pre-intervention=0, post-intervention=1), for group *k* (control group=0, treated group=1), at time *t* (pre-intervention implementation <0, month of intervention implementation=0, post-intervention implementation>0):

$$\begin{aligned}\mathrm{Outcome}_{jkt} = {} & \beta_0 + \beta_1 \mathrm{time}_t + \beta_2 \mathrm{group}_k + \beta_3 \mathrm{time}_t \mathrm{group}_k + \beta_4 \mathrm{level}_{jt} + \beta_5 \mathrm{trend}_{jt} \\ & + \beta_6 \mathrm{booth_hours}_{jkt} + \beta_7 \mathrm{trend}_{jt} \mathrm{group}_k \\ & + \beta_8 \mathrm{RxOpioids}_{jkt} + \beta_9 \mathrm{OAT}_{jkt} + \beta_{10} \mathrm{naloxone}_{jkt} + \varepsilon_{jkt}\end{aligned}$$

Where β_0 is the outcome rate intercept for the control; β_1 represents the pre-intervention temporal trend for the control's outcome rate; β_2 indicates the pre-intervention difference between the treated group's outcome rate intercept and the controls (level difference); β_3 captures the pre-intervention difference between treated and control groups' temporal trends; β_4 represents the difference in the control outcome rate immediately post-intervention compared with the control outcome rate at the beginning of the pre-intervention observation period (level difference); β_5 indicates the change in temporal trend for the control outcome rate post-intervention compared with pre-intervention; β_6 is the effect of the booth-hours on the treated group's outcome rate; and β_7 indicates the difference between treated and control groups' temporal trends post-implementation (i.e., the treated groups change in trend *relative* to the control group's change in trend, β_5). We also adjusted for other relevant time-varying confounders following the disjunctive cause criterion for confounder selection such that all covariates are known or potential causes of the exposure (i.e., OPS/CTS implementation) and/or the outcome (i.e., opioid-related ED visits, hospitalizations or death) (VanderWeele & Shpitser, 2011). Finally, we corrected for seasonality using harmonic terms, and used Newey-West standard errors to account for autocorrelation identified using plots of residuals.

Since the initial OPS/CTSs was implemented at different times across the nine PHUs, we applied a multiple baseline approach (i.e. using intervention time instead of calendar time)(Hawkins, Sanson-Fisher, Shakeshaft, D'Este, & Green, 2007) to measure the effect of booth-hours on population-level ED visits, hospitalizations, and deaths. We aggregated the data across treated PHUs with well-fitted synthetic controls and report the results of these aggregate analyses and their sensitivity analyses in the main text. We also report the disaggregated results per PHU treated/synthetic control pair in the supplementary material.

For sensitivity analysis, we tested the effects of the Good Samaritan Drug Overdose Act(Government of Canada, 2018) across all treated/synthetic control pairs (not shown here), aggregated all treated PHU/synthetic control pairs irrespective of fit, and terminated the observation period to before March 2020 and the onset of COVID-19 related service restrictions and border closures.

All analyses were conducted using R version 4.0.5(R Core Team, 2014). All data used for this study are publicly available through the Ontario Opioid Tool, Ontario Drug Policy Research Network, news articles and OPS/CTS listed hours of operation (see Supplement). All results are reported using 95% CI and accompanying p-values. Because we created a unique synthetic control per treated PHU *per* outcome, we did not use a p-value correction for interpreting our results. However, a simple Bonferroni correction per treated unit assuming we were using the *same* synthetic control across all three outcomes would change the accepted p-value from 0.05 to 0.017.

RESULTS

When the first unsanctioned OPSs began operating in Toronto and Ottawa, Hamilton (n=9, 1.58 per 100,000), Niagara Region (n=7, 1.53 per 100,000), Toronto (n=27, 0.92 per 100,000), Peel (n=11, 0.73 per 100,000), Ottawa (n=7, 0.70 per 100,000), and York (n=7, 0.59 per 100,000) reported the highest opioid-related mortality counts; while Kingston-Frontenac-Lennox-Addison (n=5, 2.42 per 100,000), North Bay-Parry Sound (n=3, 2.34 per 100,000), Peterborough (n=3, 2.11 per 100,000), Thunder Bay (n=3, 1.95 per 100,000), and Haldimand-Norfolk (n=2, 1.79 per 100,000) had the highest mortality rates. Meanwhile, small, less urban PHUs (Chatham-Kent, Eastern Ontario, Haliburton-Kawartha-Pine Ridge, Hastings-Prince Edward, Leeds-Grenville, Porcupine, Renfrew, Timiskaming, and Wellington-Dufferin-Guelph) reported no mortality events. These patterns persisted for ED and hospitalization events such that the largest, most urban PHUs did not have the highest event rates despite high event counts. Except for Niagara and Thunder Bay, treated and potential control units in the donor pool were sufficiently similar in population demographics and outcomes (i.e. none of the treated units were outside the convex hull of the donor pool), overdose risks and relevant policies; with no known external shocks specific to control units (Bouttell, Craig, Lewsey, Robinson, & Popham, 2018). Niagara and Thunder Bay's outcomes were consistently outside the convex hull in the six months prior to intervention implementation such that suitable synthetic controls could not be established across any of the outcomes. The same occurred for London ED visits and hospitalizations, and Kingston hospitalizations. In these cases, we excluded the poorly matched treated PHU/synthetic control pairs from the primary aggregate analyses but report results where they are included as well (see Table 4).

Tables 1 and 2 show the predictor weights and public health units used to create the synthetic controls per treated unit by outcome.

Table 1. Synthetic control predictor weights [here]

ED=Emergency department; Hosp=Hospitalization; OAT=Opioid agonist treatment; pop=population

Table 2. Synthetic control donor public health units [here]

Table 3 shows the balance between treated and synthetic controls' predictors compared with the overall sample means at time of intervention implementation, per outcome. Notably, perfect balance is not observed across all predictors for each treated-synthetic control unit given the weight of each predictor per outcome ranged from 0.00 (no effect in creating synthetic control for that outcome) to 0.85 for persons prescribed opioids for pain management when creating Thunder Bay's synthetic control for ED visits (treated: 4412, synthetic control: 4408, sample mean: 3838).

Table 3. Characteristics of treated units, synthetic controls (per outcome) and overall sample mean at time of intervention [here]

ED=Emergency department; Hosp.=Hospitalizations; pop.=population; Mort.=Mortalities

Although there is no consensus on a root mean square prediction error (RMSPE) threshold distinguishing well-matched from inadequately constructed synthetic controls, using the RMSPE and outputs from the adjusted segmented regression (β_3), we found the monthly pre-intervention outcome trends were parallel for well-matched treated/synthetic control PHU pairs (Table 4, Supplementary Table 3). As expected, differences in pre-intervention trends were observed for London ED visits (0.17, 95% CI: 0.03, 0.30; p-value=0.0169) and hospitalizations (0.05, 95% CI: 0.02, 0.08; p-value=0.0027); Kingston hospitalizations (0.10, 95% CI: 0.06, 0.15; p-value<0.0001); Thunder Bay ED visits (0.23, 95% CI: 0.08, 0.38; p-value=0.0031) and deaths (0.08, 95% CI: 0.01, 0.15; p-value=0.0207). Trend differences were also observed for Hamilton (0.04, 95% CI: 0.01, 0.07; p-value=0.0180) and Waterloo deaths (0.05, 95% CI: 0.02, 0.08; p-value=0.0053) compared with their respective synthetic controls; but not for Niagara and its synthetic control pair. In our sensitivity analyses where we restricted analysis to observations prior to COVID-19 related public health measures (i.e., observation period ending Feb 2020), differences between treated and synthetic control trends persisted for Kingston hospitalizations (0.10, 95% CI: 0.05, 0.16; p-value=0.0005), and Thunder Bay ED visits (0.24, 95% CI: 0.06, 0.42; p-value=0.0126) and deaths (0.07, 95% CI: 0.02, 0.13).

Table 4. Aggregate analysis: crude, adjusted, restricted to PHUs with well-fitting synthetic controls, and analysis ending the post-intervention observation period on Feb 2020 (also restricted to well-fitted synthetic controls)[here]

*Adjusted with robust standard errors generated using Newey-West method

The results from the aggregate analysis using the entire observation period (March 2021, inclusive) and restricting to treated PHUs with well-fitting synthetic controls found no effect of booth-hours on ED visits (0.00, 95% CI: -0.01, 0.01; p-value=0.6684), hospitalizations (0.00, 95% CI: 0.00, 0.00; p-value=0.9710) or deaths (0.00, 95% CI: 0.00, 0.00; p-value=0.2466) after controlling for other co-occurring interventions and underlying epidemiological trends. The results were the same when we restricted the observation period to before COVID-19 public health measures were implemented (February 2020, inclusive): 0.00 ED visits (95% CI: -0.01, 0.01; p-value=0.7591), 0.00 hospitalizations (95% CI: 0.00, 0.00; p-value=0.9016), and 0.00 deaths (95% CI: 0.00, 0.00; p-value=0.2371).

Notably, aggregate results revealed a change in epidemiological trend in the synthetic controls (β_5) for -0.23 ED visits per month (95% CI: -0.35, -0.12; p-value=0.0002) and -0.04 deaths per month (95% CI: -0.05, -0.02; p-value<0.0001); with no additional statistically significant change in trend for treated units (β_7) for ED

visits (-0.15, 95% CI: -0.49, 0.19; p-value=0.3882), hospitalizations (-0.02, 95% CI: -0.05, 0.01; p-value=0.1618) or deaths (-0.02, 95% CI: -0.05, 0.02; p-value=0.3559), respectively. In other words, the aggregate analysis found the same small decline in trend post-implementation across both treated and control units. Finally, aggregate analyses also revealed that OAT reduced ED visits (-0.20, 95% CI: -0.35, -0.05; p-value=0.0103) and deaths (-0.04, 95% CI: -0.05, -0.03; p-value=<0.0001); while prescription opioids for pain management modestly increased deaths (0.0008, 95% CI: 0.0002, 0.0015; p-value=0.0157). These results persisted in our sensitivity analyses.

Figure 1. Controlled interrupted time series plots of aggregate analyses restricted to treated PHUs with well-fitted synthetic controls [here]

Results for individual treated/synthetic control PHUs were mixed. Note that many coefficients were assessed relative to the p=0.05 level. There were 102 coefficients (4 coefficients for 3 outcomes across 9 PHUs) that would be described in the following text if their p-value had been below 0.05:

ED visits

Per booth-hour, ED visits increased in Guelph (0.02, 95% CI: 0.01, 0.03; p-value=0.0059) but declined in Ottawa (-0.0023, 95% CI: -0.0037, -0.0008; p-value=0.0021) and London (-0.02, 95% CI: -0.03, 0.00; p-value=0.0177). Meanwhile, prescription opioids for pain management increased ED visits in London (0.01, 95% CI: 0.00, 0.01; p-value=0.0266), Kingston (0.01, 95% CI: 0.01, 0.01; p-value=0.0001), Thunder Bay (0.0044, 95% CI: 0.0003, 0.0084; p-value=0.0380) and Niagara (0.01, 95% CI: 0.00, 0.01; p-value=0.0463).

Our sensitivity analyses found no effects of booth-hours on ED visits but prescription opioids for pain management decreased ED visits in Toronto (-0.0027, 95% CI: -0.0052, -0.0001; p-value=0.04555), and Ottawa (-0.0039, 95% CI: -0.0059, -0.0019; p-value=0.0003).

Hospitalizations

There was no statistically significant effect of booth-hours on hospitalizations. However, prescription opioids for pain management increased hospitalizations in Kingston (0.0017, 95% CI: 0.0001, 0.0032; p-value=0.0350) but decreased hospitalizations in Waterloo (-0.0022, 95% CI: -0.0032, -0.0011; p-value=0.0002). Results from the sensitivity analyses found no effect of opioids for pain management on hospitalizations in the period before COVID-19 public health measures were implemented.

Deaths

Per booth-hour, deaths declined in London (-0.0039, 95% CI: -0.0062, -0.0015; p-value=0.0020), and Thunder Bay (-0.0038, 95% CI: -0.0074, -0.0002; p-value=0.0396). Prescription opioids for pain management increased deaths in London (0.0010, 95% CI: 0.0001, 0.0019; p-value=0.0349). Paradoxically, OAT reduced

deaths in London (-0.02, 95% CI: -0.03, -0.01; p-value<0.0001) but increased deaths in Hamilton (0.01, 95% CI: 0.00, 0.03; p-value=0.0169). Naloxone kits reduced deaths in Toronto (-0.0043, 95% CI: -0.01, 0.00) and London (-0.0027, 95% CI: -0.0042, -0.0012; p-value=0.0004).

Our sensitivity analyses found the effects of prescription opioids for pain management (0.0013, 95% CI: 0.0003, 0.0022; p-value=0.0113) and OAT (-0.02, 95% CI: -0.03, -0.01; p-value<0.0001) persisted in London; while OAT (0.01, 95% CI: 0.01, 0.02; p-value=0.0005) and naloxone (0.0077, 95% CI: 0.0022, 0.0131; p-value=0.0074) increased deaths in Kingston.

DISCUSSION

Our aggregate analyses found no effects of booth-hours on opioid-related ED visits, hospitalizations, or deaths; but OAT reduced ED visits and deaths. Small, but significant reductions in ED visits (Ottawa, London) and deaths (London, Thunder Bay) were observed locally; while there was an increase in ED visits for Guelph. In other words, 5 of the 36 coefficients for the local effects of booth-hours appeared to be significant at the p=0.05 level.

Our models estimated 18.76 (95% CI: -34.61, -7.50) and 16.47 (95% CI: -28.67, -7.17) ED visits averted per month in Ottawa and London, respectively; and an additional 10.34 (95% CI: 5.17, 15.51) ED visits per month for Guelph. Assuming each visit cost the health care system approximately $304 (Canadian Institute for Health Information, 2020), this equates to $5703 and $5007 saved, and $3134 incurred per month, respectively. Further, we found London's and Thunder Bay's CTSs averted 3.21 (95% CI: -5.11, -1.24) and 2.90 (95% CI: -5.63, -0.15) deaths per month, respectively. Using a very modest value of life of $1,000,000 (Griffiths & Vadlamudi, 2016) this equates to $3,210,000 and $2,900,000 saved monthly. However, we *do not* encourage limiting cost-effectiveness or cost-benefit exercises to overdose events averted since costs of operating OPSs, for example, while minimal (e.g. $20,367/month each, 40 hours/week) still include other program, administrative, phone, data management and IT expenses that are not specific to these outcomes (Ministry of Health and Long-Term Care, 2018a, 2018b). To better determine if OPS/CTSs are a cost-effective or even cost-saving intervention, we recommend incorporating costs averted from reduced transmission of blood borne infections and other drug use injuries (i.e. skin, soft tissue, and vascular infections and their sequelae) (Panagiotoglou et al., 2021).

Extensive research on the effects of supervised consumption sites (and their variants) has yet to show consistent population-level benefits. Until recently, all the evidence on the effectiveness of supervised consumption sites in Canada was based on Vancouver's Insite. First implemented in September 2003, Insite is in the Downtown Eastside – a unique neighborhood with one of the highest concentrations of people who use illicit drugs globally (Hayashi et al., 2019). Numerous studies have explored Insite's effectiveness on drug related harms and acceptability in the community. Among the most rigorous of these, a study led by Marshall

et al. demonstrated Insite decreased the local fatal overdose rate by 35% from 253.1 to 165.1 deaths per 100,000 person-years (Marshall BDL, Milloy MJ, Wood E, Montaner JS, & Kerr T, 2011). Differences in magnitude between Marshall et al.'s findings and ours may be a consequence of several important methodological differences. Their analysis compared overdose mortality rates for the population within 500m of Insite to the rest of the city's population pre- (1 January 2001 to 20 September 2003) and post-implementation (21 September 2005 to 31 December 2005). While innovative at the time, this seminal paper did not account for underlying epidemiological trends or other co-occurring and time-varying interventions, nor restricted comparison to neighborhoods comparable to the Downtown Eastside, potentially overestimating the effect of Insite on fatal overdose rates.

More recently, a mathematical model of the individual and synergistic effects of British Columbia's harm reduction interventions (OAT, take home naloxone, and OPS) found all three play a significant role in stemming overdose deaths, with OPS averting 290 deaths (credible interval (CrI): 160 – 350) over 21 months (Michael A. Irvine et al., 2019). Differences in the effect sizes between their findings and ours may be, in part, owing to a key assumption underlying their model: in the absence of medical or peer intervention each overdose results in death (M. A. Irvine et al., 2018; Michael A. Irvine et al., 2019). While overdoses do cause life-threatening bradypnea (also referred to as opioid induced respiratory depression, classified as < 12 breaths per minute), respiratory distress, particularly when mild, can spontaneously resolve (Ballantyne, 2007; Toronto Public Health, 2022). In fact, in Irvine et al.'s 2019 paper, although the baseline death rate was set to 1.0 with large credible intervals, posterior estimates showed this to be much smaller (0.0682, 95% CrI: 0.0663 – 0.0701) (Michael A. Irvine et al., 2019). While the authors do not speak to this discrepancy directly in the 2019 paper, they do *briefly* acknowledge a large difference between the prior and posterior estimates in a prior paper examining the effects of BC's take home naloxone program (M. A. Irvine et al., 2018). This uncertainty around the baseline death rate per overdose event coupled with differences in population substance use preferences, patterns and geographic diffusion; extent of fentanyl contamination of the illicit drug supply; observation period (i.e. the BC paper examined the effects of these interventions when most services *and* overdose events remained concentrated within Vancouver's Downtown Eastside); and delivery models of OPS/CTSs may further explain why Irvine et al. observed substantially larger effect sizes for OPSs in British Columbia than we do here.

Our study is not the first to find a lack of effect of supervised consumption sites on mortality, but it is the largest. An evaluation of Sydney, Australia's supervised injection centre (NCHECR, 2007) and another of OPSs in mid-sized communities on Vancouver Island (The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018) both noted a decrease in local paramedic attendance, but no effect on overdose related mortality. The authors of these reports considered the rarity of fatal events and subsequent

challenges with study power as possible explanations for the absence of a measurable effect; and specific to Sydney, a co-occurring decline in the local heroin supply.

Our results also agree with simpler analysis we conducted to evaluate British Columbia's recently implemented OPSs (Panagiotoglou, 2022). In both studies, we used controlled interrupted time series and reported aggregate, population-level results. However, in the BC study we were not able to control for other time-varying interventions nor the intensity of the intervention itself. Despite these differences, both studies found a lack of effect on hospitalization and mortality rates. The BC analysis found OPSs reduced ED visits whereas our Ontario analysis did not. This may be due to differences in provincial OPS guidelines for medical care follow-up after on-site overdose reversal (BC Centre on Substance Use, 2017). Finally, both studies found a decline in the death rate trend in their respective aggregate control populations which was mirrored in the treated units (Panagiotoglou, 2022). While the cause of this decline in underlying epidemiological trend is not clear, it may be a combination of gradual changes in opioid drug use behaviour (e.g. prioritizing using substances with a peer, testing substances for contaminants), the public's perception of substance use disorder, and law enforcement activity. The effects of this cultural shift may be imperceptibly small at the local treated/control unit level, but discernable in the aggregate analyses, and worth additional exploration. This common change in trend for the treated/control unit dyads lends additional credence to the comparability of the groups. Alternatively, a change in the control's trend that was not also observed in the treated unit would indicate substantial and problematic differences between the populations.

The lack of observed effect of OPS/CTSs on our outcomes may be a consequence of access barriers first described elsewhere. Work examining successful implementation and uptake of OPSs in British Columbia found persisting stigma and police presence reduced their social acceptability and use by at-risk populations (Collins et al., 2019). Meanwhile, hours of operation, facility capacity, and absence of safe inhalation rooms limited their effectiveness (The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018). Similar barriers have been described in qualitative work on Ontario's OPSs (Foreman-Mackey, Bayoumi, Miskovic, Kolla, & Strike, 2019). This may also explain why OAT reduces deaths, since patients receiving OAT have already overcome challenges to access.

Despite concerns that harm reduction interventions may encourage risky behaviour (Hedlund, 2000) and therefore explain the lack of observed effects in our study, a team examining the prevalence of unintentional overdose in a longitudinal cohort of people who inject drugs in Toronto has found no evidence of risk compensation (Scheim et al., 2021). Finally, while drug use and fentanyl consumption, in particular, have increased since March 2020 (Statistics Canada, 2021), these consumption changes do not explain the lack of observed effects in our sensitivity analyses. Together, our results suggest the effectiveness of OPS/CTSs is more modest than described elsewhere, and/or context specific.

Strengths and limitations

Our study had some limitations. We used reported hours of operation gleaned from OPS/CTS websites, online platforms (i.e. Facebook and Twitter) or reported by local media to estimate booth-hours provided per month. Where information was missing, we assumed the number of booths matched the number included in public reports or plans prior to opening. Despite exhaustive searches, we were unable to confirm the number of booth-hours provided at Toronto's The Works' two recently implemented hotel-based resident sites, and for Ottawa's mobile site, and did not include these sites in our monthly booth-hour estimates. For COVID-19 related changes to services, if no explicit update on the number of booths was available, we assumed the number was adjusted to meet public health guidelines (e.g. where three booths normally operated side-by-side, we assumed the middle booth was temporarily unavailable until guidelines were revised) (Public Health Ontario, 2020). These assumptions and exclusions may underestimate the number of booth-hours per PHU and overestimate the marginal effect of each additional booth-hour. However, they do not detract from the overall observed effect that booth-hours had no effect on ED visit, hospitalization or death rates in our aggregate analyses.

With respect to naloxone kits distributed by community-based organizations (separate from those dispensed by participating pharmacies), we used annual reports to estimate monthly counts whenever more granular data were not available (e.g. distribution campaign or blitz for a specific period). Again, this likely introduced error to the month-to-month number of kits distributed but should have minimal effect on the overall impact of naloxone kits readily available for private use.

While we cannot definitively rule out that travel from control to treated PHUs did not dilute treatment effects, using maps to confirm OPS/CTSs were well within PHU boundaries and assuming distance-decay effects described in other studies apply here (Marshall BDL et al., 2011; The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018), it is unlikely that population mobility across boundaries explains the absence of observed effects. This lack of evidence of spillover effects satisfies a critical assumption of synthetic control methods (Bouttell et al., 2018).

The response to the COVID-19 pandemic introduced some challenges for our study, including delays in public reporting of outcome data by Ontario Public Health and public health units (e.g. naloxone kits distributed). However, we were still able to observe at least fourteen months (and over three years for early adopters Toronto and Ottawa) of intervention effect post-implementation after allowing for a three month intervention ramp up period as recommended by others (The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018). Further, by including periods after federal/provincial COVID-19 emergency orders were implemented in March 2020, we were able to test the effects of booth-hours with dramatic changes in capacity within distinct populations (Box, Jenkins, & Reinsel, 2011). Although we were

able to adjust for reduced service capacity and changes in naloxone distribution, and OAT and prescription opioids for pain management dispensing because of social distancing measures, we were unable to directly adjust for changes in toxicity of the illicit drug supply following border closures. Potential increases in drug toxicity along with temporary reductions in booth-hours and clients' hesitation to use services may explain the spikes in ED visit and mortality rates observed immediately after March 2020 (Supplementary Figures 1 and 3, respectively) (Beard et al., 2019; Statistics Canada, 2021).

Finally, we were not able to create sufficiently well-fitted synthetic controls for all our treated PHUs across all three outcomes. Some of this was anticipated given that outcome rates for Niagara and Thunder Bay were outside the convex hull of rates observed in the donor pool in the six months leading to the implementation of the intervention. To work around this, we reported the individual effects between treated and synthetic controls for all pairs in the supplement (Table 3). For our main results, we reported the findings from our aggregate analyses restricted to treated PHU/synthetic control pairs where there was no observed pre-intervention trend differences between the two and whose RMSPE was small (n_{ED}=6, n_{Hosp}=5, and n_{Deaths}=7). We also reported for the reader the aggregate results including all treated PHU/synthetic control pairs (n=9). While likely biased, these results also found no effect of booth-hours on our outcomes. Although novel approaches to address the challenges of pre-treatment fit such as Augmented Synthetic Control Methods are becoming available, we opted to combine the traditional synthetic controls as first developed by Abadie et al. with interrupted time series methods to maximize the accessibility of this study (Ben-Michael, Feller, & Rothstein, 2021).

By comparing outcome rates between treated PHUs and synthetic controls with excellent fit, controlling for concomitant time-varying interventions, conducting extensive sensitivity analyses, pooling the data using a multiple baseline approach for aggregate analyses, and comparing the plausibility of our results with site specific use statistics – ours is the first rigorous, province-wide study on the effects of supervised consumption sites on a population outside British Columbia. Our results suggest that the effects of OPS/CTSs are modest and/or context specific at best.

CONCLUSION

Supervised consumption sites are among a set of harm reduction interventions increasingly implemented across Canada to stem the ongoing opioid overdose epidemic. Our study found no effect of booth-hours on ED visit, hospitalization or deaths across Ontario, and small local effects. Although OPS/CTSs do not appear in this study to have beneficial population level effects on overdose-related ED visits, hospitalizations or deaths, they may improve access to other critical services not captured here (e.g. primary care, mental health, housing/social services) and reduce infections and injuries from illicit drug use.

Table 1. Synthetic control predictor weights

Predictor	Toronto			Hamilton			Kingston			London			Niagara		
	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths
Persons dispensed opioids for pain	0.21	0.19	0.16	0.27		0.12	0.32	0.17	0.02	0.12	0.18	0.05			
Persons receiving OAT	0.38		0.23	0.12	0.05	0.20	0.12		0.63	0.27		0.01		0.09	0.20
Naloxone kits distributed	0.08	0.12	0.08	0.03	0.01		0.01		0.01		0.30		0.34	0.24	0.19
Alcohol-related hospitalization rate	0.01		0.12	0.06		0.15		0.07		0.01		0.05	0.02		0.09
Alcohol-related ED visit rate	0.10	0.35		0.01		0.09	0.09	0.75	0.01	0.30	0.45	0.20	0.01		
Median household income		0.01	0.05		0.01	0.24			0.03	0.06		0.38	0.29	0.40	0.31
Proportion population unemployed	0.13	0.14	0.10	0.48	0.02	0.02	0.43		0.29	0.03	0.05	0.14	0.22	0.25	0.03
Proportion adult population without high school degree	0.03	0.16	0.23	0.04	0.87	0.15	0.03					0.15	0.13	0.01	0.18
Proportion visible minority	0.05	0.02	0.02		0.04	0.03	0.01	0.01	0.01	0.22	0.01	0.03			

Predictor	Ottawa			Thunder Bay			Guelph			Waterloo		
Persons dispensed opioids for pain	0.62	0.44	0.57	0.85	0.79		0.08	0.37	0.54		0.39	0.07
Persons receiving OAT	0.04		0.02				0.59		0.17	0.06		0.02
Naloxone kits distributed	0.02	0.08						0.23			0.20	
Alcohol-related hospitalization rate	0.09	0.08	0.16		0.01		0.24		0.01			0.07
Alcohol-related ED visit rate		0.11							0.02	0.15	0.26	0.40
Median household income	0.14		0.25	0.04		0.05	0.08	0.38	0.06	0.74		
Proportion population unemployed	0.04	0.19		0.01		0.74	0.01		0.07	0.04		0.13
Proportion adult population without high school degree	0.07				0.20	0.20		0.03	0.12			
Proportion visible minority		0.09		0.09		0.01					0.14	0.31

Table 2. Synthetic control donor public health units

Public Health Unit	Toronto			Hamilton			Kingston			London		
	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths
Algoma			0.09									
Brant County				0.19	0.15	0.30	0.26	0.17	0.22	0.08		
Chatham-Kent											0.20	0.09
Durham Region		0.18										
Eastern Ontario											0.26	
Grey Bruce				0.04					0.24			
Haldimand-Norfolk				0.28		0.07						
Haliburton-Kawartha-Pine Ridge												
Halton Region							0.22	0.07	0.01			
Hastings Prince Edward												
Lambton											0.16	
Leeds-Grenville-Lark			0.06					0.08				0.54
North Bay Parry Sound												
Northwestern	0.24		0.01	0.03	0.13	0.02		0.03	0.14	0.27	0.18	
Peel	0.40	0.67	0.50		0.07					0.16	0.19	
Peterborough				0.13	0.17	0.26	0.30	0.19	0.15	0.12	0.01	0.14
Porcupine												
Renfrew												
Simcoe Muskoka	0.21		0.34	0.34	0.48				0.22			
Sudbury		0.03				0.35	0.22	0.30		0.36		
Timiskaming												
Windsor-Essex												0.23
York	0.15	0.12					0	0.15				
PHU with non-zero weights	4	4	5	6	5	5	4	7	6	5	6	4

Public Health Unit	Niagara			Ottawa			Thunder Bay			Guelph			Waterloo		
	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths
Algoma															
Brant County	0.13	0.13	0.26				0.20	0.01	0.38	0.07		0.28	0.34	0.01	0.19
Chatham-Kent														0.01	
Durham Region			0.01		0.18									0.01	
Eastern Ontario		0.01	0.01		0.08						0.18			0.34	
Grey Bruce	0.01	0.01	0.01							0.19	0.24	0.27	0.27	0.01	0.22
Haldimand-Norfolk			0.01											0.01	
Haliburton-Kawartha-Pine Ridge		0.01	0.01											0.01	
Halton Region			0.03	0.10	0.27					0.25	0.33	0.12	0.26	0.37	0.34
Hastings Prince Edward	0.17	0.24	0.01											0.01	
Lambton		0.03	0.24											0.01	
Leeds-Grenville-Lark	0.01	0.01	0.01	0.02										0.01	
North Bay Parry Sound							0.26	0.34							
Northwestern			0.01	0.01	0.07	0.05	0.08	0.39	0.35	0.04				0.03	
Peel			0.03	0.21	0.02	0.35									
Peterborough	0.58	0.54	0.25					0.20	0.09						
Porcupine											0.09			0.01	
Renfrew		0.01	0.01											0.01	
Simcoe Muskoka			0.01	0.25	0	0.21				0.29		0.01			
Sudbury			0.05				0.47		0.18				0.12	0.01	0.09
Timiskaming								0.01							
Windsor-Essex	0.08	0.01	0.03					0.03							
York			0.02	0.41	0.38	0.39				0.17	0.14	0.32		0.15	0.16
PHU with non-zero weights	6	10	18	6	6	4	4	6	4	6	5	5	4	16	5

Table 3. Characteristics of treated units, synthetic controls (per outcome) and overall sample mean at time of intervention; rate per 100,000 population

	Synthetic controls					Synthetic controls					Synthetic controls				
	Treated	**ED**	**Hosp.**	**Mort.**	**Sample Mean**	**Treated**	**ED**	**Hosp.**	**Mort.**	**Sample Mean**	**Treated**	**ED**	**Hosp.**	**Mort.**	**Sample Mean**
Predictor			**Toronto**					**Hamilton**					**Kingston**		
Opioid prescriptions rate	1950	2727	2110	2941	4024	3875	4026	3744	4184	3912	3581	3686	3583	3872	3895
OAT rate	206	396	206	306	491	454	583	6001	767	516	484	630	612	598	518
Naloxone kits distributed rate	20	15	6	15	15	84	70	69	73	50	77	69	67	76	55
Alcohol-related hospitalization rate	193	273	235	348	284	239	382	431	270	292	248	287	248	326	292
Alcohol-related ED visit rate	742	1315	366	525	690	655	660	1132	742	733	722	606	722	1174	733
Median household income	66479	81586	88302	79549	71580	71081	72881	74265	70060	72925	72287	77405	76611	71142	72925
Population unemployed (%)	8	8	8	8	8	7	7	8	8	8	7	7	8	7	8
Adult population without high school degree (%)	16	20	17	18	20	19	20	19	19	20	14	17	18	20	20
Visible minority (%)	52	34	53	34	11	20	5	10	5	11	7	10	13	5	11
Predictor			**London**					**Niagara**					**Ottawa**		
Opioid prescriptions rate	3459	3771	3592	4068	3971	4281	4130	4122	3891	3822	2166	2355	2312	2295	4024
OAT rate	563	740	552	428	507	689	688	688	689	530	164	223	236	245	491
Naloxone kits distributed rate	51	46	28	35	32	100	103	100	100	81	30	9	7	9	15
Alcohol-related hospitalization rate	192	216	195	238	292	323	345	342	301	292	131	285	207	275	284
Alcohol-related ED visit rate	510	1736	1213	524	733	619	668	664	617	733	526	414	583	570	690
Median household income	66201	73065	71293	68949	72925	66675	66788	66714	72135	72925	86793	89200	92978	87385	71580
Population unemployed (%)	8	9	8	7	8	8	8	8	8	8	7	7	7	7	8
Adult population without high school degree (%)	16	21	21	18	20	17	18	18	17	20	12	17	16	18	20
Visible minority (%)	18	13	15	7	11	9	6	5	9	11	27	38	33	43	11
Predictor			**Thunder Bay**					**Guelph**					**Waterloo**		
Opioid prescriptions pain rate	4412	4408	4406	3953	3838	2874	2994	2876	2945	3924	24901	3262	2491	2731	3662
OAT rate	1729	845	906	895	528	236	319	237	337	514	278	475	278	344	543
Naloxone kits distributed rate	175	131	118	121	76	39	38	27	33	44	190	187	76	139	143
Alcohol-related hospitalization rate	181	393	494	232	292	92	319	207	226	292	229	231	229	229	291
Alcohol-related ED visit rate	2857	1012	2316	2084	733	611.25	602	472	427	733	446	540	525	464	779
Median household income	69420	68968	66446	70047	72925	85428	85518	85414	83124	72925	80782	80745	88956	88282	74270
Population unemployed (%)	8	9	10	8	8	6	7	7	6	8	7	7	7	7	8
Adult population without high school degree (%)	22	21	22	22	20	18	17	18	18	20	18	17	16	16	19
Visible minority (%)	4	4	3	5	11	12	18	18	23	11	20	11	20	20	11

ED=Emergency department; Hosp.=Hospitalizations; Mort. = Mortality

Table 4. Aggregate analysis: crude, adjusted, restricted to PHUs with well-fitting synthetic controls, and analysis ending the post-intervention observation period on Feb 2020 (also restricted to well-fitted synthetic controls)

	Crude		Adjusted (all PHU pairs)		Restricted (well-fit PHU pairs)		Restricted, Pre-COVID	
Emergency department visits	**(95% CI)**	**P-value**	**(95% CI)**	**P-value**	**(95% CI)**	**P-value**	**(95% CI)**	**P-value**
Pre-intervention trend, control (β_1)	**0.18 (0.07, 0.29)**	**0.0010**	**0.18 (0.05, 0.31)**	**0.0083**	**0.26 (0.10, 0.42)**	**0.0021**	**0.25 (0.08, 0.41)**	**0.0045**
Pre-intervention level difference, treated vs. control (β_2)	**2.92 (1.41, 4.43)**	**0.0002**	**2.92 (0.82, 5.01)**	**0.0081**	**2.68 (0.32, 5.04)**	**0.0290**	**2.50 (0.12, 5.12)**	**0.0656**
Pre-intervention trend difference, treated vs. control (β_3)	**0.05 (0.01, 0.08)**	**0.0113**	**0.05 (0.02, 0.08)**	**0.0053**	0.02 (-0.03, 0.07)	0.3606	0.00 (-0.06, 0.06)	0.9616
Post-intervention level difference, control (β_4)	-0.09 (-0.61, 0.43)	0.7305	-0.09 (-0.83,0.65)	0.8113	-0.19 (-1.03, 0.64)	0.6558	-0.26 (-1.05, 0.53)	0.5172
Post-intervention trend difference, control (β_5)	**-0.12 (-0.20, -0.04)**	**0.0036**	**-0.12 (-0.21, -0.03)**	**0.0109**	**-0.23 (-0.35, -0.12)**	**0.0002**	**-0.27 (-0.47, -0.06)**	**0.0130**
Booth-hours (β_6)	0.00 (-0.01, 0.00)	0.8791	0.00 (-0.01, 0.01)	0.9223	0.00 (-0.02, 0.01)	0.6684	0.00 (-0.01, 0.01)	0.7591
Post-intervention trend difference, treated vs. control (β_7)	**-0.15 (-0.27, -0.04)**	**0.0087**	-0.15 (-0.39, 0.09)	0.2146	-0.15 (-0.49, 0.19)	0.3882	-0.20 (-0.64, 0.24)	0.3756
Prescription opioids (β_8)			0.00 (0.00, 0.00)	0.5559	0.00 (0.00, 0.00)	0.1725	0.00 (0.00, 0.00)	0.4325
OAT (β_9)			-0.08 (-0.18,0.02)	0.1249	**-0.20 (-0.35, -0.05)**	**0.0103**	**-0.19 (-0.35, -0.03)**	**0.0249**
Naloxone kits (β_{10})			0.00 (-0.01, 0.02)	0.7036	0.01 (-0.01, 0.02)	0.2960	**0.02 (0.01, 0.03)**	**0.0044**
Hospitalizations								
Pre-intervention trend, control (β_1)	0.01 (-0.02, 0.04)	0.5827	0.01 (-0.01, 0.03))	0.4812	0.00 (-0.01, 0.02)	0.6786	0.02 (-0.01, 0.04)	0.1771
Pre-intervention level difference, treated vs. control (β_2)	0.58 (-1.28, 2.43)	0.5438	0.58 (-0.87, 2.03)	0.4391	0.30 (-0.30, 0.91)	0.3305	0.26 (-0.24, 0.76)	0.3071
Pre-intervention trend difference, treated vs. control (β_3)	0.01 (-0.01, 0.02)	0.2655	0.01 (0.00, 0.02)	0.1830	0.01 (-0.01, 0.02)	0.3910	0.00 (-0.01, 0.02)	0.5340
Post-intervention level difference, control (β_4)	-0.05 (-0.22, 0.11)	0.5264	-0.05 (-0.19, 0.09)	0.4597	0.00 (-0.18, 0.17)	0.9651	-0.01 (-0.20, 0.18)	0.9407
Post-intervention trend difference, control (β_5)	-0.01 (-0.03, 0.02)	0.5668	-0.01 (-0.02, 0.01)	0.3550	0.00 (-0.02, 0.01)	0.7259	-0.02 (-0.05, 0.02)	0.3331
Booth-hours (β_6)	0.00 (0.00, 0.00)	0.7313	0.00 (0.00, 0.00)	0.5864	0.00 (0.00, 0.00)	0.9710	0.00 (0.00, 0.00)	0.9016
Post-intervention trend difference, treated vs. control (β_7)	-0.03 (-0.07, 0.01)	0.1250	**-0.03 (-0.05, -0.01)**	**0.0171**	-0.02 (-0.05, 0.01)	0.1618	-0.03 (-0.07, 0.01)	0.2000
Prescription opioids (β_8)			0.00 (0.00, 0.00)	0.7570	0.00 (0.00, 0.00)	0.9780	**0.00 (0.00, 0.00)**	**0.0312**
OAT (β_9)			0.00 (-0.02, 0.01)	0.6692	-0.01 (-0.02, 0.01)	0.5817	-0.01 (-0.03, 0.01)	0.3725
Naloxone kits (β_{10})			0.00 (0.00, 0.00)	0.8669	0.00 (0.00, 0.00)	0.8243	0.00 (0.00, 0.00)	0.6703

Deaths								
Pre-intervention trend, control (β_1)	**0.06 (0.04, 0.09)**	**0.0000**	**0.06 (0.05, 0.08)**	**0.0000**	**0.06 (0.04, 0.07)**	**<0.0001**	**0.06 (0.03, 0.08)**	**<0.0001**
Pre-intervention level difference, treated vs. control (β_2)	**1.79 (0.92, 2.66)**	**0.0001**	**1.79 (1.22, 2.36)**	**0.0000**	**0.73 (0.53, 0.93)**	**<0.0001**	**0.37 (0.22, 0.53)**	**<0.0001**
Pre-intervention trend difference, treated vs. control (β_3)	**0.01 (0.00, 0.02)**	**0.0080**	**0.01 (0.01, 0.02)**	**0.0000**	0.00 (0.00, 0.01)	0.2468	**0.00 (-0.01, 0.01)**	**0.8106**
Post-intervention level difference, control (β_4)	-0.01 (-0.15, 0.13)	0.8591	-0.01 (-0.08, 0.05)	0.6998	0.01 (-0.12, 0.14)	0.9325	-0.02 (-0.18, 0.14)	0.8366
Post-intervention trend difference, control (β_5)	**-0.03 (-0.05, -0.01)**	**0.0080**	**-0.03 (-0.04, -0.02)**	**0.0001**	**-0.04 (-0.05, -0.02)**	**<0.0001**	**-0.04 (-0.06, -0.02)**	**0.0022**
Booth-hours (β_6)	0.00 (0.00, 0.00)	0.3414	0.00 (0.00, 0.00)	0.2023	0.00 (0.00, 0.00)	0.2466	0.00 (0.00, 0.00)	0.2371
Post-intervention trend difference, treated vs. control (β_7)	0.00 (-0.03, 0.04)	0.8373	0.00 (-0.03, 0.03)	0.8321	-0.02 (-0.05, 0.02)	0.3559	-0.02 (-0.05, 0.02)	0.3937
Prescription opioids (β_8)			**0.00 (0.00, 0.00)**	**0.0282**	**0.00 (0.00, 0.00)**	**0.0157**	**0.00 (0.00, 0.00)**	**0.0293**
OAT (β_9)			**-0.03 (-0.05, -0.02)**	**<0.0001**	**-0.04 (-0.05, -0.03)**	**<0.0001**	**-0.03 (-0.05, -0.02)**	**<0.0001**
Naloxone kits (β_{10})			**0.00 (-0.01, 0.00)**	**0.0005**	0.00 (0.00, 0.00)	0.2166	0.00 (0.00, 0.00)	0.8176

Restricted models excluded: ED (London, Niagara, Thunder Bay); Hospitalizations (London, Kingston, Niagara, Thunder Bay); Deaths (Niagara, Thunder Bay) based on pre-intervention outcome rates and reported root mean square prediction errors.

REFERENCES

Abadie, A., Diamond, A., & Hainmueller, J. (2011). Synth: An {R} Package for Synthetic Control Methods in Comparative Case Studies. *Journal of Statistical Software, 42*(13), 1-17.

BC Centre on Substance Use, B. M. o. H. (2017). Supervised Consumption Services: operational guidance. In.

BC Ministry of Health. (2017). Overdose Prevention. Retrieved from https://www2.gov.bc.ca/gov/content/overdose/what-you-need-to-know/overdose-prevention

Beard, E., Marsden, J., Brown, J., Tombor, I., Stapleton, J., Michie, S., & West, R. (2019). Understanding and using time series analyses in addiction research. *Addiction, 114*(10), 1866-1884. doi:10.1111/add.14643

Bilinski, A. (2021). *Goldilocks and the Pre-Intervention Time Series: How Long is 'Just Right' and the Parallel Trends Implications*. McGill University. Montreal, QC. Retrieved from https://www.mcgill.ca/epi-biostat-occh/files/epi-biostat-occh/abilinski-announcement-11jan2021_0.pdf

Bouttell, J., Craig, P., Lewsey, J., Robinson, M., & Popham, F. (2018). Synthetic control methodology as a tool for evaluating population-level health interventions. *J Epidemiol Community Health, 72*(8), 673-678. doi:10.1136/jech-2017-210106

Box, G. E., Jenkins, G. M., & Reinsel, G. C. (2011). *Time Series Analysis: Forecasting and Control*: John Wiley & Sons.

Canadian Centre on Substance Abuse, & Canadian Community Epidemiology Network on Drug Use. (2016). *CCENDU Bulletin: The Availability of Take-Home Naloxone in Canada*. Retrieved from Ottawa, ON: https://www.ccsa.ca/sites/default/files/2019-05/CCSA-CCENDU-Take-Home-Naloxone-Canada-2016-en.pdf

Canadian Institute for Health Information. (2018). *Opioid-Related Harms in Canada, December 2018*. Retrieved from Ottawa, ON: https://www.cihi.ca/sites/default/files/document/opioid-related-harms-report-2018-en-web.pdf

Canadian Pharmacists Association. (2017). *Environmental Scan: Access to naloxone across Canada*. Retrieved from Ottawa, ON: https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/Environmental%20Scan%20-%20Access%20to%20Naloxone%20Across%20Canada_Final.pdf

Castanho Silva, B., & DeWitt, M. (2020). SCtools: Extensions for Synthetic Controls Analysis. R package version 0.3.1.

Caulkins, J. P., Pardo, B., & Kilmer, B. (2019). Supervised consumption sites: a nuanced assessment of the causal evidence. *Addiction, 114*(12), 2109-2115. doi:https://doi.org/10.1111/add.14747

Collins, A. B., Boyd, J., Mayer, S., Fowler, A., Kennedy, M. C., Bluthenthal, R. N., . . . McNeil, R. (2019). Policing space in the overdose crisis: A rapid ethnographic study of the impact of law enforcement practices on the effectiveness of overdose prevention sites. *International Journal of Drug Policy, 73*, 199-207. doi:https://doi.org/10.1016/j.drugpo.2019.08.002

Degli Esposti, M., Spreckelsen, T., Gasparrini, A., Wiebe, D. J., Bonander, C., Yakubovich, A. R., & Humphreys, D. K. (2020). Can synthetic controls improve causal inference in interrupted time series evaluations of public health interventions? *Int J Epidemiol, 49*(6), 2010-2020. doi:10.1093/ije/dyaa152

Foreman-Mackey, A., Bayoumi, A. M., Miskovic, M., Kolla, G., & Strike, C. (2019). 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario. *International Journal of Drug Policy, 73*, 135-140. doi:https://doi.org/10.1016/j.drugpo.2019.09.019

Gogolishvili, D., & Wasdell, M. (2020). *Effectiveness of take-home naloxone programs and availability of naloxone nasal spray in different jurisdictions*. Retrieved from Toronto, ON: https://www.ohtn.on.ca/rapid-response-effectiveness-of-take-home-naloxone-programs-and-availability-of-naloxone-nasal-spray-in-different-jurisdictions/

Government of Canada. (2018, 03 August 2018). About the Good Samaritan Drug Overdose Act. Retrieved from https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/about-good-samaritan-drug-overdose-act.html

Government of Ontario. (2020). Ontario Demographic Quarterly: Highlights of first quarter 2020. Retrieved from https://www.ontario.ca/page/ontario-demographic-quarterly-highlights-first-quarter-2020

Hedlund, J. (2000). Risky business: safety regulations, risk compensation, and individual behavior. *Injury Prevention, 6*(2), 82-89. doi:10.1136/ip.6.2.82

Irvine, M. A., Kuo, M., Buxton, J. A., Balshaw, R., Otterstatter, M., Macdougall, L., . . . Gilbert, M. (2019). Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. *Addiction, 114*(9), 1602-1613. doi:https://doi.org/10.1111/add.14664

Izenberg, D., Iroanyah, N., & Thompson, S. (2018). Uninsured patients in Ontario: People get sicker, the system pays more. *Healthy Debate*. Retrieved from https://healthydebate.ca/2018/07/topic/uninsured-patients-ontario/

Kennedy, M. C., Hayashi, K., Milloy, M. J., Wood, E., & Kerr, T. (2019). Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLOS Medicine, 16*(11), e1002964. doi:10.1371/journal.pmed.1002964

Marshall BDL, Milloy MJ, Wood E, Montaner JS, & Kerr T. (2011). Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet, 377*(9775), 1429-1437.

Ministry of Health and Long-Term Care. (2018). *Consumption and treatment services: Application guide*. Retrieved from Toronto, ON: https://health.gov.on.ca/en/pro/programs/opioids/docs/CTS_application_guide_en.pdf

NCHECR. (2007). *Sydney Medically Supervised Injecting Centre Evaluation Report No. 4: Evaluation of service operation and overdose-related events*. Retrieved from Sydney, NSW: https://kirby.unsw.edu.au/sites/default/files/kirby/report/EvalRep4SMSIC.pdf

Ontario Agency for Health Protection and Promotion (Public Health Ontario). (2020). *Interactive Opioid Tool*. Retrieved from Toronto, ON: https://www.publichealthontario.ca/en/data-and-analysis/substance-use/interactive-opioid-tool

Ontario Ministry of Health, & Ontario Ministry of Long-Term Care. (2018). Applications Now Open for Overdose Prevention Sites. Retrieved from https://www.health.gov.on.ca/en/news/bulletin/2018/hb_20180111.aspx

Panagiotoglou, D. (2022). Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series. *PLoS One, 17*(3), e0265665. doi:10.1371/journal.pone.0265665

Pivot Legal Society. (2020). Canada's supervised consumption and overdose prevention sites. Retrieved from https://www.pivotlegal.org/scs_ops_map

Potier C, Laprévote V, Dubois-Arber F, Cottencin O, & Rolland B. (2014). Supervised injection services: what has been demonstrated? A systematic literature review. *Drug Alcohol Depend, 1*(145), 48-68.

Public Health Ontario. (2020). *COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites*. Retrieved from Toronto, Ontario: https://www.oha.com/Bulletins/CTS%20COVID-19%20Guidance%20Document%20-%20March%2023%202020%20Shared.pdf

R Core Team. (2014). R: A language and environment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing.

Russell, C., Imtiaz, S., Ali, F., Elton-Marshall, T., & Rehm, J. (2020). 'Small communities, large oversight': The impact of recent legislative changes concerning supervised consumption services on small communities in Ontario, Canada. *Int J Drug Policy, 82*, 102822. doi:10.1016/j.drugpo.2020.102822

Scheim, A. I., Bouck, Z., Tookey, P., Hopkins, S., Sniderman, R., McLean, E., . . . Werb, D. (2021). Supervised consumption service use and recent non-fatal overdose among people who inject drugs in Toronto, Canada. *International Journal of Drug Policy, 87*, 102993. doi:https://doi.org/10.1016/j.drugpo.2020.102993

Special Advisory Committee on the Epidemic of Opioid Overdoses. (2022). *Opioid- and Stimulant-related Harms in Canada*. Retrieved from Ottawa: Public Health Agency of Canada: https://health-infobase.canada.com/substance-related-harms/opioids-stimulants/

Statistics Canada. (2020). *Life tables, 2016/2018*. Retrieved from Ottawa: https://www150.statcan.gc.ca/n1/daily-quotidien/200128/dq200128a-eng.htm

Strike, C., & Watson, T. M. (2019). Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. *International Journal of Drug Policy, 71*, 178-182. doi:https://doi.org/10.1016/j.drugpo.2019.02.005

Tam, T. (2018). Commentary - Building the evidence base for sustained public health response to the opioid epidemic in Canada. [Commentaire - Constituer un ensemble de données probantes au service d'une action soutenue en santé publique en réponse à la crise des opioïdes au Canada]. *Health promotion and chronic disease prevention in Canada : research, policy and practice, 38*(6), 221-222. doi:10.24095/hpcdp.38.6.01

The Evaluation of Overdose Prevention Sites Working Group, & Lori Wagar. (2018). *Evaluation of Overdose Prevention Sites: Campbell River, Courtenay, Cowichan Valley, and Port Alberni - FINAL REPORT*. Retrieved from Victoria, BC: https://www.islandhealth.ca/sites/default/files/2018-10/evaluation-OPS-report.pdf

VanderWeele, T. J., & Shpitser, I. (2011). A new criterion for confounder selection. *Biometrics, 67*(4), 1406-1413. doi:10.1111/j.1541-0420.2011.01619.x



Figure 1. Controlled interrupted time series plots of aggregate analyses restricted to treated PHUs with well-fitted synthetic controls

Supplementary Material

Table of Contents

Table 1. Overdose Prevention Site and Consumption and Treatment Services hours of operation and booths/spaces available (pg. 2)

Table 2. Naloxone kits dispensed by Public Health Units and community-based organizations (pg. 5)

Table 3. Crude and adjusted segmented regression output for treated/synthetic control unit pairs and aggregate analysis (pg. 6)

Figure 1. Controlled interrupted time-series of opioid-related ED visits plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 9)

Figure 2. Controlled interrupted time-series of opioid-related hospitalizations plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 10)

Figure 3. Controlled interrupted time-series of opioid-related mortalities plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 11)

Supplement Data Sources (pg. 12)

Table 1. Overdose Prevention Site and Consumption and Treatment Services hours of operation and booths/spaces available

Site / Address	Hours	Booths	Date	Notes	Source
Toronto Public Health - The Works **277 Victoria St.** **Toronto**	M – S: 4pm – 10pm	3	Aug 21 2017	Closed Mar 18 – Apr 17 2020	(CBC News, 2017; Medical Officer of Health, 2018; Surveillance & Epidemiology, 2021)
	M – S: 10 am – 10pm	6	Nov 8 2017		(CBC News, 2017; Draaisma & Lucs, 2020)
	M – S: 10 am – 10pm		Jul 12 2018		(Toronto Drop-In Network, 2018)
	Su: 11am – 5pm M – S: 10am – 10pm		Oct 14 2018		(Surveillance & Epidemiology, 2021)
	Su: 11am – 5pm M – S: 10am – 10pm		May 24 2019		(Harm Reduction TO, 2019)
	Su: 11am – 6pm M – S: 1:30pm – 8pm	2	Apr 18 2020		(Draaisma & Lucs, 2020; Surveillance & Epidemiology, 2021)
	Su: 11am – 5pm M – S: 10am – 10pm		May 11 2020		(Toronto Public Health, 2020)
Fred Victor **145 Queen St. E** **Toronto**	Su – S: 6pm – 12am	3	Feb 21 2018	Assume change in hours/capacity began March 18 2020	(CBC News, 2018b)
	Su – S: 6pm – 12am		July 12 2018		(Toronto Drop-In Network, 2018)
	Su – S: 8:30am – 12am		May 24 2019		(Harm Reduction TO, 2019)
	Su – S: 8:30am – 11pm	2	Apr 6 2020		(Fred Victor, 2020; Toronto Central Health Line, 2021b)
	Su – S: 8:30am – 11pm		Aug 5 2020		(Pride Toronto, 2020)
Moss Park OPS **134 Sherbourne St.** **Toronto**	Su: 12pm – 6pm T – S: 12pm – 6pm	5	Aug 12 2017	Assume no change in hours but reduced capacity began with updated spring hours	(Contenta, 2019; CTVNews.ca Staff, 2017; Mullin, 2017)
	Su: 12pm – 6pm T – S: 12pm – 10pm		Jul 12 2018		(Contenta, 2019; Toronto Drop-In Network, 2018)
	Su: 12pm – 6pm T – S: 12pm – 10pm	3	Apr 18 2020		(Draaisma & Lucs, 2020)
Parkdale Queen West CHC **168 Bathurst St.** **Toronto**	M, T, R: 10am – 6pm W: 1pm – 6pm F: 9am – 5pm	4	Mar 16 2018	Assume hours of operation match office hours at opening	(News Staff, 2018; Parkdale Queen West Community Health Centre, 2018b)
	M, W, R: 9:30 am – 8pm T: 1pm – 8pm F: 9:30am – 4:30pm		Jul 12 2018		(Toronto Drop-In Network, 2018)
	M, T, R: 9:30 am – 8pm W: 1pm – 8pm F: 9:30am – 4:30pm		May 24 2019		(Harm Reduction TO, 2019)
	M, T, R: 10am – 6pm W: 1pm – 6pm F: 9:30am – 4:30pm	2	Mar 18 2020		(City of Toronto, 2021; Draaisma & Lucs, 2020; Parkdale Queen West Community Health Centre, 2020)
Parkdale Queen West CHC **1229 Queen St. W**	Su – S: 12pm – 12am	3	Aug 16 2018		(Parkdale Queen West Community Health Centre, 2018a)
	M, T, R: 12pm – 8pm W : 1pm – 8pm F: 12pm – 5pm		May 24 2019		(Harm Reduction TO, 2019)
	M, T, R: 10am – 6pm W: 1pm – 6pm	2	March 2020		(City of Toronto, 2021; Draaisma & Lucs, 2020; Parkdale Queen West Community Health Centre, 2020)

	F: 9:30am – 4:30pm				
	M, T, R: 10am – 8pm W: 1pm – 6pm F: 9am – 5pm		Dec 22 2020		(Toronto Central Health Line, 2021a)
Regent Park CHC **465 Dundas St. E** **Toronto**	M, W – F: 9:30am – 6:30 pm T: 12pm – 6:30pm	2	April 27 2018	Assume same hours as first listed for July 2018	(Jones, 2018)
	M, W – F: 9:30am – 6:30 pm T: 12pm – 6:30pm		July 12 2018		(Toronto Drop-In Network, 2018)
	M, W – F: 9am – 6:30pm T: 12pm – 6:30pm		May 24 2019		(Harm Reduction TO, 2019)
	M, W – F: 9:30am – 4:30pm T: 12pm – 4:30pm		Mar 2020		(City of Toronto, 2021)
	M, W – F: 9:30am – 4pm T: 12pm – 6:30pm		May 1 2020		(Regent Park Community Health Centre, 2020)
South Riverdale CHC **955 Queen St. E** **Toronto**	M, T, R: 9:30am – 8pm W, F: 9:30 am – 5pm	4	Jul 12 2018		(Toronto Drop-In Network, 2018)
	M, T, R: 9:30am – 8pm W, F: 9:30 am – 5pm		May 24 2019		(Harm Reduction TO, 2019)
Street Health OPS **338 Dundas St. E** **Toronto**	M – F: 11am – 4pm	2	Jun 27 2018	Assume same hours as first listed for July 2018	(Kolla, Penn, & Long, 2019; Street Health Community Health Centre, 2018)
	M – F: 11 am – 4pm		Jul 12 2018		(Toronto Drop-In Network, 2018)
	M, W – F: 9:30am – 4pm T: 11am – 4pm		May 24 2019		(Harm Reduction TO, 2019)
St. Stephen's Community House OPS **260 Augusta St.** **Toronto**	M – F: 7:30am – 3:30pm	2	Apr 25 2018		(St. Stephen's Community House, 2018; Toronto Drop-In Network, 2020)
	Su: 8 am – 11:00am M – F: 7:30 am – 11:30am		Jul 12 2018		(Toronto Drop-In Network, 2018)
	Su – F: 8am – 2pm		May 24 2019		(Harm Reduction TO, 2019)
Urban Core **71 Rebecca St.** **Hamilton**	Su: 4pm – 10:30pm M, T, R, F: 10:30am – 10:30pm W: 12:30 – 10:30pm S: 4pm – 10:30pm	3	Jun 5 2018	Assume change in booths beginning March 2020	(City of Hamilton, 2018; Hamilton Urban Core Community Health Centre, 2018)
	S, S: 4pm – 10:30pm M, T, R, F: 10:30am – 10:30pm W: 12:30 – 10:30pm	2	Mar 18 2020		
	Su – S: 4pm – 10:30pm		Nov 30 2020		(Hamilton Public Library, 2020)
Street Health Centre and HARS Integrated Health Hub **661 Montreal St.** **Kingston**	Su – S: 4pm – 10pm	4	Jul 29 2018		(Ferguson, 2018; Hurdle, 2019)
	Su – S: 11am – 7pm		Apr 2020		(Kingston Frontenac Lennox and Addincton Public Health, 2020)
OPS /Carepoint CTS **#30 – 186 King St.** **London**	Su, S: 11am – 4pm M – F: 10 am – 4pm	4	Feb 12 2018	Assume changes in booths beginning March 2020	(CBC News, 2018a; Kitching, 2018; Middlesex-London Health Unit, 2018)
	Su – S: 9:30am – 9pm		Aug 5 2019		(Middlesex-London Health Unit, 2018)

	Su – S: 9:30am – 9pm	2	Mar 18 2020		(Lupton, 2020)
Positive Living Niagara	Su – S: 9:30am – 8:30pm	4	Dec 3 2018	Assume changes in booths beginning March 2020	(Clementson, 2019)
105 Queenston St. Niagara	Su – S: 9:30am – 8:30pm		Apr 13 202		(The Welland Tribune, 2020)
Overdose Prevention Ottawa 307 St. Patrick St. Ottawa	Su – S: 6pm – 9pm	28	Aug 25 2017	8 injection spaces, 20 inhalation spaces Last day: Nov 9 2017	(Ottawa Prevention, 2018)
Ottawa Public Health SIS	Su – S: 9am – 9pm	2	Sep 26 2017	Assume cuts to services began Jan 1 2020	(Raymond, 2018a)
	Su – S: 9am – 9pm	3	Feb 6 2017		(Raymond, 2018a)
179 Clarence St. Ottawa	M – F: 9am – 5pm	2	Nov 6 2019		(CBC News, 2019b)
Sandy Hill CHC	Su – S: 8am – 8pm	5	Apr 17 2018	Assume changes in booths beginning March 18 2020	(Crawford, 2018)
221 Nelson St. Ottawa	Su – S: 8am – 8pm	3	May 17 2020		(Jones, 2020)
Inner City Health	24/7	8	Nov 1 2017	Assume additional booths added towards end of first year of operation (Aug 2018)	(DelVillano, de Groh, Morrison, & Do, 2019; Payne, 2017)
230 Murray St. Ottawa	24/7	12	Jul 3 2019		(Fagan, 2019)
	24/7	13	Nov 6 2019		(CBC News, 2019b)
	24/7	6	Mar 18 2020		(Reynolds, 2021)
	24/7	8	Nov 2020		(Reynolds, 2021)
Somerset West CHC OPS	M – F: 9am – 4 pm	4	May 2 2018		(Raymond, 2018b; Whan, 2018)
55 Eccles St. Ottawa	Su – S: 8:30am – 7:30pm		Jun 2019		(Pivot Legal Society, 2019, 2020)
Path 525 – NorWest Community Centre	M – F: 9am – 5pm	4	Nov 27 2018	Assume number of booths planned are number in operation	(Diaczuk, 2018)
525 Simpson St.	M – S: 10am – 6pm		Mar 24 2020		(211 Ontario North, 2020; NorWest Community Health Centres, 24 March 2020)
Guelph CHC	Su – S: 10am – 5pm	2	May 5 2018	Assume changes in hours beginning March 2020; No mention of fewer booths	(Groleau, 2018; Wellington-Duffering-Guelph, 2018)
150 Duke St. W	Su – S: 9am – 4:30pm	4	Feb 22 2020		(Armstrong, 2020)
Guelph	M – F: 9am – 5pm		April 2020		(Centre, 2020)
Sanguen Health Centre	Su – S: 9am – 9pm	2	Oct 15 2019		(CBC News, 2019a)
150 Duke St. Waterloo	Su – S: 9am – 9pm	5	Oct 9 2020		(Senoran, 2020)

CHC = Community Health Centre; CTS = Consumption and Treatment Service; SIS = Safe injection site; OPS=Overdose Prevention Site; Days of the week: Su=Sunday, M=Monday, T=Tuesday, W=Wednesday, R=Thursday, F=Friday, S=Saturday;

Monthly booth hours per treated public health unit are: $y_{it} = \sum_{n=1}^{N}(b_{nt} \times h_{nt})$

where *y* is the total booth-hours per treated public health unit *i* at month *t*, *b* is the number of booths in operation at a specific site *n*, and *h* is the number of hours operated that month.

Table 2. Naloxone kits dispensed by Public Health Units and community-based organizations

PHU	2014	2015	2016	2017	2018	2019	2020	2021	Source
Algoma				355	590	737			(Kelly, 2019; The Corporation of the City of Sault Ste. Marie, 2019; The Sault Star, 2019)
Brant County				172	428	1365*	1282*	5726*	(Brant County Board of Health, 2018; Brant County Health Unit, 2017, 2022)
Chatham-Kent				92	381	342	429	46~	(Chatham - Kent Public Health, 2017, 2021; Municipality of Chatham-Kent, 2021)
Hamilton			924	3402	6412	17705	16613	17046§	(City of Hamilton, 2022; Paddon, 2018)
Durham Region				458 →					(Tadrous, Shearer, Martins, Campbell, & Gomes, 2019)
Eastern Ontario				13 →					(Tadrous et al., 2019)
Grey-Bruce				437	1337			2434	(Public Health Grey Bruce, 2020, 2021)
Haldimand-Norfolk				0	352				(Health and Social Services Haldimand and Norfolk, 2018; Tadrous et al., 2019)
Haliburton					297	802			(Haliburton, 2020; Tadrous et al., 2019)
Halton Region				226 →		223	320	418	(Halton Region, 2021; Tadrous et al., 2019)
Hastings Prince Edward County			39	166	326	890			(Hastings Prince Edward County Public Health, 2019, 2021)
Kingston				456	1419				(Kingston Community Health Centres, 2019)
Lambton				508	700	2015			(Lambton Public Health, 2019; Ontario Association of Fire Chiefs, 2020; Tadrous et al., 2019)
Leeds				408 →					(Tadrous et al., 2019)
London	40	98	168	848	2381	5289			(Middlesex-London Health Unit, 2021)
Niagara				1482 →		4761	5885	7876	(Tadrous et al., 2019) (Niagara Region, 2021)
North Bay				500	2000	4000			(CBC News, 2019c)
Northwestern				825	816				(Northwestern Health Unit, 2020a, 2020b)
Ottawa			115	1300	5500				(Ottawa Board of Health, 2019; Ottawa Public Health, 2017, 2018)
Peel				366	1376				(Region of Peel, 2019)
Peterborough				833					(Tadrous et al., 2019)
Porcupine				224	906	2656			(Porcupine health unit, 2018, 2020)
Renfrew				53	197	233			(Renfrew County and District Health Unit, 2018, 2019, 2020)
Simcoe Muskoka			462	1700	1620	2595			(Paddon, 2018; Simcoe Muskoka District Health Unit, 2019, 2020)
Sudbury				1235		10010	15438*	24822*	(Public Health Sudbury District, 2021a, 2021b; Tadrous et al., 2019)
Thunder Bay	34	32	35	554	2022	4216	6846		(Thunder Bay District Health Unit, 2022)
Timiskaming				18 →					(Tadrous et al., 2019)
Toronto	← 2000			7717	42294	51577	67012		(Medical Officer of Health, 2018, 2019, 2020, 2021)
Waterloo			677	4703	6782				(Region of Waterloo, 2018; Regional Municipality of Waterloo, 2019)

Guelph	581 →	1419		(Tadrous et al., 2019; Wellington-Dufferin-Guelph, 2019)
Windson-Essex	1461 →	3059	5378	(Tadrous et al., 2019; Windsor-Essex County Health Unit, 2021)
York	560 →		2380	(Regional Municipality of York, 2019; Tadrous et al., 2019)

*Monthly counts available
§Quarterly counts available
~Most recent avaliable
→ July 1 2017 – June 30 2018
←2011 – 2015, inclusive

Table 3. Crude and adjusted segmented regression output for treated/synthetic control unit pairs and aggregate analysis

	Emergency department visits per 100,000 population				Hospitalizations per 100,000 population				Deaths per 100,000 population			
	Crude (95% CI)	P-value	Adj.* (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
Toronto												
Pre-intervention trend, control (β_1)	0.09 (0.03, 0.15)	0.0043	0.10 (0.00, 0.19)	0.0449	0.00 (-0.01, 0.01)	0.4510	0.01 (0.00, 0.03)	0.1601	0.02 (0.00, 0.03)	0.0365	0.02 (-0.02, 0.06)	0.3322
Pre-intervention level difference, treated vs. control (β_2)	1.09 (0.16, 2.02)	0.0221	1.43 (-2.64, 5.49)	0.4925	0.07 (-0.08, 0.21)	0.3638	0.10 (-0.11, 0.31)	0.3600	0.25 (0.02, 0.47)	0.0309	0.99 (-0.70, 2.69)	0.2511
Pre-intervention trend difference, treated vs. control (β_3)	0.08 (0.01, 0.16)	0.0257	0.08 (-0.08, 0.24)	0.3135	0.01 (0.00, 0.02)	0.2459	0.01 (-0.01, 0.02)	0.2625	0.01 (0.00, 0.03)	0.1036	0.02 (-0.01, 0.04)	0.1666
Post-intervention level difference, control (β_4)	0.23 (-0.69, 1.15)	0.6196	0.67 (-0.82, 2.16)	0.3799	0.08 (-0.07, 0.22)	0.3011	0.10 (-0.02, 0.22)	0.0908	-0.01 (-0.23, 0.21)	0.9266	0.15 (-0.07, 0.36)	0.1964
Post-intervention trend difference, control (β_5)	-0.03 (-0.10, 0.04)	0.4581	-0.02 (-0.11, 0.07)	0.5922	-0.01 (-0.02, 0.00)	0.2072	-0.01 (-0.03, 0.01)	0.2316	0.00 (-0.02, 0.02)	0.8404	0.01 (-0.02, 0.03)	0.6191
Booth-hours (β_6)	0.00 (0.00, 0.00)	0.2515	0.00 (-0.01, 0.01)	0.9141	**0.00 (0.00, 0.00)**	**0.0432**	0.00 (0.00, 0.00)	0.7052	0.00 (0.00, 0.00)	<0.0001	0.00 (0.00, 0.00)	0.2953
Post-intervention trend difference, treated vs. control (β_7)	-0.10 (-0.19, -0.01)	0.0375	-0.07 (-0.25, 0.10)	0.4130	0.00 (-0.01, 0.01)	0.9808	0.00 (-0.02, 0.01)	0.7071	-0.01 (-0.03, 0.02)	0.5592	0.00 (-0.02, 0.02)	0.9519
Prescription opioids (β_8)			0.00 (0.00, 0.00)	0.7997			0.00 (0.00, 0.00)	0.6894			0.00 (0.00, 0.00)	0.4659
OAT (β_9)			0.00 (-0.01, 0.01)	0.9308			-0.01 (-0.02, 0.01)	0.2226			0.00 (-0.01, 0.02)	0.6339
Naloxone kits (β_{10})			-0.01 (-0.03, 0.01)	0.2030			0.00 (0.00, 0.00)	0.0858			0.00 (-0.01, 0.00)	**0.0264**
Ottawa												
Pre-intervention trend, control (β_1)	0.06 (0.02, 0.11)	0.0080	0.04 (-0.07, 0.15)	0.5218	0.00 (-0.01, 0.02)	0.5143	0.00 (-0.01, 0.02)	0.6516	0.00 (-0.01, 0.02)	0.6449	0.01 (-0.02, 0.03)	0.6596
Pre-intervention level difference, treated vs. control (β_2)	0.40 (-0.31, 1.10)	0.2699	0.66 (-4.25, 5.56)	0.7934	-0.04 (-0.24, 0.16)	0.6880	0.18 (-0.60, 0.97)	0.6479	0.19 (-0.01, 0.39)	0.0590	0.26 (-0.89, 1.42)	0.6562
Pre-intervention trend difference, treated vs. control (β_3)	0.02 (-0.03, 0.08)	0.4254	0.01 (-0.04, 0.07)	0.6369	0.00 (-0.02, 0.01)	0.6065	0.00 (-0.02, 0.01)	0.4868	0.01 (0.00, 0.03)	0.1557	0.01 (-0.01, 0.03)	0.2499
Post-intervention level difference, control (β_4)	0.75 (0.07, 1.44)	0.0315	0.78 (0.06, 1.51)	0.0362	-0.07 (-0.26, 0.12)	0.4461	-0.08 (-0.25, 0.09)	0.3786	0.12 (-0.08, 0.31)	0.2439	0.09 (-0.14, 0.33)	0.4356
Post-intervention trend difference, control (β_5)	-0.04 (-0.10, 0.01)	0.0940	-0.03 (-0.12, 0.07)	0.5794	-0.01 (-0.02, 0.01)	0.4591	0.00 (-0.02, 0.01)	0.4795	0.01 (-0.01, 0.02)	0.2386	0.01 (-0.01, 0.03)	0.4353
Booth-hours (β_6)	0.00 (0.00, 0.00)	<0.0001	0.00 (0.00, 0.00)	**0.0022**	0.00 (0.00, 0.00)	0.3459	0.00 (0.00, 0.00)	0.4107	**0.00 (0.00, 0.00)**	**0.0007**	0.00 (0.00, 0.00)	0.0712
Post-intervention trend difference, treated vs. control (β_7)	0.07 (0.00, 0.14)	0.0497	0.05 (-0.02, 0.13)	0.1729	0.01 (-0.01, 0.02)	0.5815	0.00 (-0.01, 0.02)	0.5694	-0.01 (-0.02, 0.01)	0.5711	0.00 (0.00, 0.00)	0.8476
Prescription opioids (β_8)			0.00 (0.00, 0.00)	0.6270			0.00 (0.00, 0.00)	0.1752			0.00 (0.00, 0.00)	0.7740
OAT (β_9)			0.01 (-0.07, 0.09)	0.8313			0.00 (-0.01, 0.01)	0.6197			0.00 (-0.01, 0.01)	0.9485
Naloxone kits (β_{10})			0.00 (0.00, 0.01)	0.3030			0.00 (0.00, 0.00)	0.3060			0.00 (0.00, 0.00)	0.3927
London												
Pre-intervention trend, control (β_1)	0.07 (-0.07, 0.20)	0.3130	**0.25 (0.06, 0.44)**	**0.0119**	**-0.03 (-0.06, 0.00)**	**0.0403**	0.01 (-0.03, 0.04)	0.6713	0.01 (-0.02, 0.03)	0.6361	**0.09 (0.06, 0.13)**	**<0.0001**
Pre-intervention level difference, treated vs. control (β_2)	**3.19 (1.00, 5.39)**	**0.0044**	2.21 (-4.29, 8.71)	0.5069	**0.67 (0.18, 1.16)**	**0.0071**	**0.93 (0.48, 1.39)**	**0.0001**	0.37 (-0.37, 0.76)	0.0676	**3.28 (2.21, 4.35)**	**<0.0001**
Pre-intervention trend difference, treated vs. control (β_3)	**0.19 (0.03, 0.36)**	**0.0243**	**0.17 (0.03, 0.30)**	**0.0169**	**0.04 (0.00, 0.08)**	**0.0344**	**0.05 (0.02, 0.08)**	**0.0027**	0.02 (-0.01, 0.05)	0.1926	0.00 (-0.03, 0.02)	0.6963
Post-intervention level difference, control (β_4)	0.95 (-1.17, 3.06)	0.3805	0.67 (-1.47, 2.81)	0.5430	0.04 (-0.43, 0.510	0.8634	0.12 (-0.25, 0.49)	0.5366	-0.02 (-0.40, 0.37)	0.9367	-0.06 (-0.46, 0.33)	0.7577
Post-intervention trend difference, control (β_5)	**0.21 (0.05, 0.37)**	**0.0096**	**0.22 (0.07, 0.37)**	**0.0062**	**0.04 (0.00, 0.07)**	**0.0344**	**0.04 (0.01, 0.06)**	**0.0077**	0.01 (-0.02, 0.04)	0.4164	**-0.04 (-0.07, -0.01)**	**0.0128**
Booth-hours (β_6)	**-0.02 (-0.03, -0.01)**	**0.0010**	**-0.02 (-0.03, 0.00)**	**0.0177**	0.00 (0.00, 0.00)	0.2789	0.00 (-0.01, 0.00)	0.1757	**0.00 (0.00, 0.00)**	**0.0408**	**0.00 (-0.01, 0.00)**	**0.0020**
Post-intervention trend difference, treated vs. control (β_7)	-0.22 (-0.44, 0.00)	0.0512	**-0.33 (-0.59, -0.06)**	**0.0164**	**-0.06 (-0.11, -0.01)**	**0.0164**	-0.11 (-0.17, -0.05)	0.0002	0.00 (-0.04, 0.04)	0.8508	-0.04 (-0.08, 0.00)	0.0518
Prescription opioids (β_8)			**0.01 (0.00, 0.01)**	**0.0266**			0.00 (0.00, 0.00)	0.7677			**0.00 (0.00, 0.00)**	**0.0349**
OAT (β_9)			-0.01 (-0.05, 0.02)	0.4498			**-0.01 (-0.02, 0.00)**	**0.0358**			**-0.02 (-0.03, -0.01)**	**<0.0001**
Naloxone kits (β_{10})			-0.01 (-0.02, 0.01)	0.3759			**0.00 (-0.01, 0.00)**	**0.0006**			**0.00 (0.00, 0.00)**	**0.0004**
Guelph												
Pre-intervention trend, control (β_1)	**0.12 (0.03, 0.20)**	**0.0050**	0.09 (-0.05, 0.23)	0.2055	0.04 (-0.01, 0.08)	0.1093	**0.06 (0.01, 0.12)**	**0.0286**	0.01 (-0.02, 0.04)	0.4588	0.02 (-0.03, 0.07)	0.4691
Pre-intervention level difference, treated vs. control (β_2)	-0.30 (-1.70, 1.11)	0.6805	1.34 (-4.77, 7.45)	0.6681	**1.10 (0.25, 1.95)**	**0.0112**	0.64 (-1.33, 2.60)	0.5261	-0.16 (-0.62, 0.30)	0.4978	-0.08 (-2.72, 2.55)	0.9511
Pre-intervention trend difference, treated vs. control (β_3)	-0.01 (-0.11, 0.10)	0.8982	0.02 (-0.10, 0.14)	0.7438	**0.09 (0.03, 0.15)**	**0.0028**	**0.10 (0.06, 0.15)**	**<0.0001**	-0.01 (-0.05, 0.02)	0.3959	-0.02 (-0.05, 0.02)	0.3969
Post-intervention level difference, control (β_4)	-0.20 (-1.53, 1.13)	0.7663	-0.07 (-1.87. 1.73)	0.9412	**-0.81 (-1.59, -0.03)**	**0.0418**	**-0.79 (-1.44, -0.15)**	**0.0181**	0.04 (-0.40, 0.47)	0.8670	0.16 (-0.26, 0.59)	0.4508
Post-intervention trend difference, control (β_5)	-0.09 (-0.18, 0.01)	0.0832	-0.06 (-0.18, 0.05)	0.2928	-0.03 (-0.08, 0.02)	0.2981	**-0.04 (-0.07, 0.00)**	**0.0422**	0.01 (-0.02, 0.04)	0.5399	0.01 (-0.03, 0.04)	0.6727
Booth-hours (β_6)	**0.02 (0.01, 0.03)**	**0.0033**	**0.02 (0.01, 0.03)**	**0.0059**	0.00 (0.00, 0.00)	0.9750	0.00 (0.00, 0.00)	0.9348	0.00 (0.00, 0.01)	0.1637	0.00 (0.00, 0.01)	0.1968
Post-intervention trend difference, treated vs. control (β_7)	**-0.14 (-0.27, -0.01)**	**0.0390**	-0.22 (-0.47, 0.03)	0.0823	**-0.14 (-0.21, -0.07)**	**0.0001**	**-0.14 (-0.22, -0.06)**	**0.0010**	-0.01 (-0.06, 0.03)	0.5120	0.00 (-0.08, 0.08)	0.9220
Prescription opioids (β_8)			0.00 (0.00, 0.00)	0.3257			**0.00 (0.00, 0.00)**	**0.0350**			0.00 (0.00, 0.00)	0.2549
OAT (β_9)			0.01 (-0.05, 0.07)	0.6800			0.00 (-0.02, 0.01)	0.5197			0.00 (-0.02, 0.02)	0.9772
Naloxone kits (β_{10})			0.00 (-0.01, 0.02)	0.5374			0.00 (0.00, 0.01)	0.6943			0.00 (0.00, 0.00)	0.6182

	Emergency department visits per 100,000 population				Hospitalizations per 100,000 population				Deaths per 100,000 population			
	Crude (95% CI)	P-value	Adj.* (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
Hamilton												
Pre-intervention trend, control (β_1)	0.12 (0.00, 0.25)	0.0595	0.01 (-0.19, 0.20)	0.9577	-0.02 (-0.07, 0.04)	0.5310	-0.01 (-0.06, 0.03)	0.5869	0.02 (-0.01, 0.06)	0.1580	-0.02 (-0.07, 0.04)	0.5736
Pre-intervention level difference, treated vs. control (β_2)	0.80 (-1.67, 3.28)	0.5249	2.95 (-0.69, 6.59)	0.0790	0.75 (-0.27, 1.77)	0.1512	0.86 (-2.86, 4.58)	0.6515	0.61 (-0.03, 1.25)	0.0637	5.10 (1.46, 8.74)	0.0072
Pre-intervention trend difference, treated vs. control (β_3)	0.02 (-0.16, 0.19)	0.8395	0.04 (-0.11, 0.19)	0.6396	0.03 (-0.04, 0.11)	0.3613	**0.05 (0.00, 0.09)**	**0.0367**	0.03 (-0.02, 0.08)	0.1917	0.04 (0.01, 0.07)	0.0180
Post-intervention level difference, control (β_4)	0.96 (-1.30, 3.23)	0.4045	1.80 (-1.74, 5.34)	0.3215	-0.45 (-1.42, 0.53)	0.3690	-0.22 (-1.08, 0.65)	0.6258	-0.02 (-0.61, 0.56)	0.9338	0.29 (-0.41, 1.00)	0.4142
Post-intervention trend difference, control (β_5)	-0.07 (-0.22, 0.08)	0.3397	0.09 (-0.12, 0.30)	0.4075	0.03 (-0.04, 0.11)	0.3415	0.04 (-0.02, 0.10)	0.2455	**0.04 (0.00, 0.08)**	**0.0450**	0.07 (0.03, 0.11)	0.0009
Booth-hours (β_6)	0.00 (-0.02, 0.02)	0.9089	0.01 (-0.02, 0.03)	0.4798	0.00 (0.00, 0.00)	0.5609	0.00 (0.00, 0.00)	0.4385	0.00 (-0.01, 0.00)	0.2068	0.00 (-0.01, 0.00)	0.7819
Post-intervention trend difference, treated vs. control (β_7)	-0.04 (-0.27, 0.19)	0.7405	-0.07 (-0.32, 0.19)	0.6093	-0.03 (-0.13, 0.07)	0.5603	-0.03 (-0.13, 0.07)	0.5082	**-0.08 (-0.14, -0.03)**	**0.0055**	**-0.07 (-0.11, -0.04)**	**0.0002**
Prescription opioids (β_8)			0.00 (0.00, 0.01)	0.0963			0.00 (0.00, 0.00)	0.4368			0.00 (0.00, 0.00)	0.7410
OAT (β_9)			0.04 (-0.02, 0.10)	0.1842			0.00 (0.00, 0.00)	0.9803			0.01 (0.00, 0.03)	0.0169
Naloxone kits (β_{10})			0.00 (-0.01, 0.02)	0.6967			0.00 (0.00, 0.00)	0.7471			0.00 (0.00, 0.00)	0.6369
Kingston												
Pre-intervention trend, control (β_1)	**0.20 (0.04, 0.35)**	**0.0119**	0.29 (0.05, 0.53)	0.0210	-0.02 (-0.06, 0.02)	0.3724	0.00 (-0.04, 0.03)	0.9475	0.02 (-0.02, 0.05)	0.2945	-0.04 (-0.09, 0.02)	0.2215
Pre-intervention level difference, treated vs. control (β_2)	0.83 (-2.14, 3.80)	0.5842	2.87 (-6.85, 12.59)	0.5637	0.56 (-0.20, 1.33)	0.1476	0.55 (-0.04, 1.14)	0.0693	-0.22 (-0.89, 0.46)	0.5263	0.84 (-0.72, 2.41)	0.2932
Pre-intervention trend difference, treated vs. control (β_3)	0.07 (-0.15, 0.28)	0.5456	0.15 (-0.05, 0.34)	0.1393	0.02 (-0.03, 0.08)	0.3735	0.04 (-0.01, 0.08)	0.1144	-0.02 (-0.07, 0.03)	0.3674	-0.01 (-0.05, 0.02)	0.4737
Post-intervention level difference, control (β_4)	-1.11 (-3.84, 1.62)	0.4250	0.66 (-2.51, 3.83)	0.6840	-0.46 (-1.18, 0.25)	0.2059	-0.35 (-0.72, 0.02)	0.0691	-0.08 (-0.70, 0.54)	0.8034	-0.14 (-0.63, 0.34)	0.5637
Post-intervention trend difference, control (β_5)	0.01 (-0.17, 0.19)	0.9188	0.01 (-0.25, 0.27)	0.9367	0.03 (-0.01, 0.08)	0.1634	0.03 (-0.02, 0.07)	0.1973	0.02 (-0.02, 0.06)	0.3492	**0.05 (0.01, 0.08)**	**0.0082**
Booth-hours (β_6)	0.00 (-0.01, 0.01)	0.6464	0.00 (-0.02, 0.01)	0.4071	0.00 (0.00, 0.00)	0.9704	0.00 (0.00, 0.00)	0.9639	0.00 (0.00, 0.00)	0.2978	0.00 (0.00, 0.00)	0.0604
Post-intervention trend difference, treated vs. control (β_7)	-0.14 (-0.39, 0.10)	0.2557	-0.17 (-0.43, 0.10)	0.2197	-0.05 (-0.12, 0.03)	0.2141	-0.06 (-0.12, 0.01)	0.1021	-0.01 (-0.07, 0.04)	0.6612	-0.01 (-0.05, 0.03)	0.6607
Prescription opioids (β_8)			**0.01 (0.01, 0.01)**	**0.0001**			0.00 (0.00, 0.00)	0.0322			0.00 (0.00, 0.00)	0.8165
OAT (β_9)			0.00 (-0.06, 0.06)	0.9730			0.00 (-0.01, 0.02)	0.6890			0.01 (0.00, 0.02)	0.0848
Naloxone kits (β_{10})			0.00 (-0.02, 0.02)	0.9864			0.00 (0.00, 0.00)	0.7921			0.00 (0.00, 0.01)	0.0948
Thunder Bay												
Pre-intervention trend, control (β_1)	**0.17 (0.00, 0.34)**	**0.0448**	0.12 (-0.01, 0.25)	0.0810	-0.02 (-0.04, 0.00)	0.1275	**-0.06 (-0.08, -0.03)**	**<0.0001**	0.01 (-0.05, 0.07)	0.7725	0.04 (-0.03, 0.11)	0.2613
Pre-intervention level difference, treated vs. control (β_2)	**4.42 (1.32, 7.53)**	**0.0052**	-4.92 (-18.37, 8.54)	0.4758	0.04 (-0.32, 0.41)	0.8167	-0.29 (-0.61, 0.31)	0.0831	1.65 (0.56, 2.74)	0.0030	2.31 (-2.93, 7.55)	0.3905
Pre-intervention trend difference, treated vs. control (β_3)	**0.23 (0.00, 0.45)**	**0.0487**	**0.23 (0.08, 0.38)**	**0.0031**	0.01 (-0.02, 0.03)	0.6470	0.00 (-0.02, 0.02)	0.8972	0.07 (-0.01, 0.15)	0.0954	0.08 (0.01, 0.15)	0.0207
Post-intervention level difference, control (β_4)	-0.44 (-3.38, 2.51)	0.7714	-0.35 (-2.94, 2.24)	0.7930	0.18 (-0.19, 0.55)	0.3442	0.06 (-0.19, 0.31)	0.6441	0.27 (-0.76, 1.30)	0.6060	0.32 (-0.75, 1.39)	0.5596
Post-intervention trend difference, control (β_5)	**0.33 (0.11, 0.54)**	**0.0029**	**0.29 (0.14, 0.44)**	**0.0002**	0.02 (-0.02, 0.07)	0.2755	0.06 (0.00, 0.11)	0.0646	0.04 (-0.04, 0.12)	0.2928	0.02 (-0.03, 0.08)	0.3806
Booth-hours (β_6)	-0.01 (-0.02, 0.00)	0.1588	-0.01 (-0.01, 0.00)	0.0530	0.00 (0.00, 0.00)	0.8935	0.00 (0.00, 0.00)	0.7029	**0.00 (-0.01, 0.00)**	**0.0219**	**0.00 (-0.01, 0.00)**	**0.0396**
Post-intervention trend difference, treated vs. control (β_7)	**-0.46 (-0.76, -0.16)**	**0.0029**	**-0.54 (-0.79, -0.30)**	**<0.0001**	0.00 (-0.08, 0.08)	0.9919	0.01 (-0.07, 0.08)	0.8927	0.01 (-0.10, 0.12)	0.8616	0.01 (-0.10, 0.13)	0.8148
Prescription opioids (β_8)			**0.00 (0.00, 0.01)**	**0.0380**			**0.00 (0.00, 0.00)**	**0.0002**			0.00 (0.00, 0.00)	0.4650
OAT (β_9)			0.01 (0.00, 0.03)	0.1641			0.01 (-0.01, 0.03)	0.2841			0.00 (-0.01, 0.01)	0.7855
Naloxone kits (β_{10})			**0.01 (0.00, 0.02)**	**0.0463**			0.00 (0.00, 0.00)	0.0625			0.00 (0.00, 0.00)	0.1951
Niagara												
Pre-intervention trend, control (β_1)	0.11 (-0.08, 0.31)	0.2606	0.19 (-0.14, 0.52)	0.2630	0.01 (-0.01, 0.03)	0.2880	0.00 (-0.05, 0.05)	0.9854	0.02 (-0.02, 0.06)	0.2633	0.01 (-0.03, 0.05)	0.6865
Pre-intervention level difference, treated vs. control (β_2)	**6.27 (2.29, 10.25)**	**0.0020**	**5.57 (2.42, 8.73)**	**0.0008**	-0.08 (-0.61, 0.45)	0.7752	-0.10 (-2.56, 2.37)	0.9395	**0.79 (0.09, 1.49)**	**0.0280**	**0.94 (0.43, 1.44)**	**0.0005**
Pre-intervention trend difference, treated vs. control (β_3)	0.26 (-0.02, 0.54)	0.0714	0.25 (-0.07, 0.57)	0.1228	0.00 (-0.03, 0.02)	0.9755	0.00 (-0.04, 0.04)	0.9861	0.02 (-0.03, 0.07)	0.3669	0.01 (-0.05, 0.06)	0.8103
Post-intervention level difference, control (β_4)	1.16 (-2.58, 4.91)	0.5422	0.67 (-2.96, 4.30)	0.7190	-0.18 (-0.70, 0.34)	0.4952	-0.19 (-0.75, 0.38)	0.5170	0.33 (-0.33, 0.99)	0.3234	0.12 (-0.70, 0.94)	0.7765
Post-intervention trend difference, control (β_5)	-0.07 (-0.32, 0.19)	0.6039	-0.08 (-0.46, 0.29)	0.6604	-0.01 (-0.03, 0.02)	0.5010	-0.01 (-0.05, 0.02)	0.5221	0.02 (-0.03, 0.06)	0.4804	0.02 (-0.3, 0.07)	0.3882
Booth-hours (β_6)	-0.02 (-0.03, 0.00)	0.0773	-0.02 (-0.04, 0.01)	0.1828	0.40 (-0.34, 1.14)	0.2890	0.07 (-1.06, 1.19)	0.9092	**0.00 (-0.01, 0.00)**	**0.0235**	0.00 (-0.01, 0.00)	0.0715
Post-intervention trend difference, treated vs. control (β_7)	-0.29 (-0.67, 0.09)	0.1320	-0.30 (-0.81, 0.20)	0.2428	-0.02 (-0.06, 0.01)	0.2232	-0.04 (-0.12, 0.04)	0.2926	0.00 (-0.06, 0.07)	0.9088	0.02 (-0.05, 0.09)	0.5627
Prescription opioids (β_8)			**0.01 (0.00, 0.01)**	**0.0463**			0.28 (-0.40, 0.95)	0.4194			0.00 (0.00, 0.00)	0.1832
OAT (β_9)			-0.06 (-0.18, 0.07)	0.3549			-0.07 (-0.20, 0.05)	0.2549			0.00 (-0.01, 0.02)	0.8184
Naloxone kits (β_{10})			0.02 (-0.01, 0.04)	0.1385			0.02 (-2.03, 2.07)	0.9873			0.00 (0.00, 0.00)	0.9168

	Emergency department visits per 100,000 population				Hospitalizations per 100,000 population				Deaths per 100,000 population			
	Crude (95% CI)	P-value	Adj.* (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
Waterloo												
Pre-intervention trend, control (β_1)	**0.17 (0.07, 0.26)**	**0.0007**	0.20 (-0.04, 0.44)	0.1124	0.00 (-0.01, 0.01)	0.8837	-0.05 (-0.08, -0.02)	0.0023	0.02 (0.00, 0.04)	0.1074	**0.18 (0.05, 0.31)**	**0.0083**
Pre-intervention level difference, treated vs. control (β_2)	-1.23 (-2.86, 0.40)	0.1398	8.47 (-3.56, 20.50)	0.1721	-0.26 (-0.66, 0.14)	0.1971	1.90 (-0.38, 4.17)	0.1027	-0.13 (-0.53, 0.27)	0.5260	**2.92 (0.82, 5.01)**	**0.0081**
Pre-intervention trend difference, treated vs. control (β_3)	-0.12 (-0.24, 0.01)	0.0664	-0.15 (-0.36, 0.06)	0.1791	-0.01 (-0.03, 0.01)	0.1961	-0.02 (-0.04, 0.00)	0.0438	-0.03 (-0.06, 0.00)	0.0560	**0.05 (0.02, 0.08)**	**0.0053**
Post-intervention level difference, control (β_4)	**-1.87 (-3.51, -0.23)**	**0.0259**	**-1.80 (-3.38, -0.23)**	**0.0281**	-0.41 (-0.88, 0.06)	0.0837	-0.44 (-0.92, 0.05)	0.0766	-0.22 (-0.62, 0.18)	0.2809	-0.09 (-0.83, 0.65)	0.8113
Post-intervention trend difference, control (β_5)	0.11 (-0.09, 0.30)	0.2727	-0.06 (-0.47, 0.35)	0.7803	0.04 (0.00, 0.08)	0.0460	0.05 (0.01, 0.09)	0.0088	0.04 (-0.01, 0.09)	0.0997	-0.12 (-0.21, -0.03)	0.0109
Booth-hours (β_6)	0.01 (-0.01, 0.02)	0.3962	0.00 (-0.01, 0.01)	0.9622	0.69 (0.03, 1.35)	0.0415	**0.73 (0.05, 1.54)**	**0.0359**	0.00 (0.00, 0.01)	0.5983	0.00 (-0.01, 0.01)	0.9223
Post-intervention trend difference, treated vs. control (β_7)	-0.15 (-0.52, 0.23)	0.4433	0.18 (-0.33, 0.69)	0.4871	-0.03 (-0.08, 0.03)	0.3645	0.05 (-0.05, 0.15)	0.2914	0.01 (-0.08, 0.11)	0.7531	-0.15 (-0.39, 0.09)	0.2146
Prescription opioids (β_8)			0.00 (0.00, 0.01)	0.6743			-0.14 (-0.54, 0.27)	0.5092			0.00 (0.00, 0.00)	0.5559
OAT (β_9)			0.05 (-0.02, 0.11)	0.1390			**-0.22 (-0.33, -0.10)**	**0.0002**			-0.08 (-0.18, 0.02)	0.1249
Naloxone kits (β_{10})			0.00 (-0.01, 0.01)	0.7658			**2.62 (0.02, 5.22)**	**0.0480**			0.00 (-0.01, 0.02)	0.7036
Aggregate												
Pre-intervention trend, control (β_1)			**0.26 (0.10, 0.42)**	**0.0021**			0.00 (-0.01, 0.02)	0.6786			**0.06 (0.04, 0.07)**	**<0.0001**
Pre-intervention level difference, treated vs. control (β_2)			**2.68 (0.32, 5.04)**	**0.0290**			0.30 (-0.30, 0.91)	0.3305			**0.73 (0.53, 0.93)**	**<0.0001**
Pre-intervention trend difference, treated vs. control (β_3)			0.02 (-0.03, 0.07)	0.3606			0.01 (-0.01, 0.02)	0.3910			0.00 (0.00, 0.01)	0.2468
Post-intervention level difference, control (β_4)			-0.19 (-1.03, 0.64)	0.6558			0.00 (-0.18, 0.17)	0.9651			0.01 (-0.12, 0.14)	0.9325
Post-intervention trend difference, control (β_5)			**-0.23 (-0.35, -0.12)**	**0.0002**			0.00 (-0.02, 0.01)	0.7259			**-0.04 (-0.05, -0.02)**	**<0.0001**
Booth-hours (β_6)			0.00 (-0.02, 0.01)	0.6684			0.00 (0.00, 0.00)	0.9710			0.00 (0.00, 0.00)	0.2466
Post-intervention trend difference, treated vs. control (β_7)			-0.15 (-0.49, 0.19)	0.3882			-0.02 (-0.05, 0.01)	0.1618			-0.02 (-0.05, 0.02)	0.3559
Prescription opioids (β_8)			0.00 (0.00, 0.00)	0.1725			0.00 (0.00, 0.00)	0.9780			**0.00 (0.00, 0.00)**	**0.0157**
OAT (β_9)			**-0.20 (-0.35, -0.05)**	**0.0103**			-0.01 (-0.02, 0.01)	0.5817			**-0.04 (-0.05, -0.03)**	**<0.0001**
Naloxone kits (β_{10})			0.01 (-0.01, 0.02)	0.2960			0.00 (0.00, 0.00)	0.8243			0.00 (0.00, 0.00)	0.2166

*Adjusted for seasonality using harmonic terms and with robust standard errors generated using Newey-West method, except for aggregate analysis which does not adjust for seasonality given multiple baseline approach



Figure 1. Controlled interrupted time-series of emergency department (ED) visits plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020; Counterfactual represents the expected outcome rates where the intervention set to 0 in the regression models



Figure 2. Controlled interrupted time-series of hospitalizations plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020; Counterfactual represents the expected outcome rates were the intervention set to 0 in the regression models



Figure 3. Controlled interrupted time-series of mortalities plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020; Counterfactual represents the expected outcome rates where the intervention set to 0 in the regression models

211 Ontario North. (2020). Norwest community health centres: Path 525. Retrieved from https://211north.ca/record/65782603/

Abadie, A., Diamond, A., & Hainmueller, J. (2011). Synth: An {R} Package for Synthetic Control Methods in Comparative Case Studies. *Journal of Statistical Software, 42*(13), 1-17.

Armstrong, K. (2020, 22 February 2020). Guelph safe injection site to double its capacity. *GuelphToday*. Retrieved from https://www.guelphtoday.com/local-news/guelph-safe-injection-site-to-double-its-capacity-2111065

Baker, A., Larcker, D., & Wang, C. (2021). *How much should we trust staggered difference-in-differences estimates*. Harvard Business School. Retrieved from https://www.hbs.edu/ris/Publication%20Files/21-112_8a5a4ab3-b9e7-447d-a0fe-a504b3890fb9.pdf

Ballantyne, J. C. (2007). Chapter 17 - Complications Associated with Systemic Opioids and Patient-controlled Analgesia. In J. M. Neal & J. P. Rathmell (Eds.), *Complications in Regional Anesthesia & Pain Medicine* (pp. 167-175). Philadelphia: W.B. Saunders.

BC Centre for Disease Control. (2019). BC Overdose Prevention Services Guide. In. Vancouver, BC: BC Centre for Disease Control.

BC Centre on Substance Use, B. M. o. H. (2017). Supervised Consumption Services: operational guidance. In.

Beard, E., Marsden, J., Brown, J., Tombor, I., Stapleton, J., Michie, S., & West, R. (2019). Understanding and using time series analyses in addiction research. *Addiction, 114*(10), 1866-1884. doi:10.1111/add.14643

Ben-Michael, E., Feller, A., & Rothstein, J. (2021). The Augmented Synthetic Control Method. *Journal of the American Statistical Association, 116*(536), 1789-1803. doi:10.1080/01621459.2021.1929245

Bernal JL, Cummins S, & Gasparrini A. (2017). Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int J Epi, 46*(1), 348-355.

Bilinski, A. (2021). *Goldilocks and the Pre-Intervention Time Series: How Long is 'Just Right' and the Parallel Trends Implications*. McGill University. Montreal, QC. Retrieved from https://www.mcgill.ca/epi-biostat-occh/files/epi-biostat-occh/abilinski-announcement-11jan2021_0.pdf

Bouttell, J., Craig, P., Lewsey, J., Robinson, M., & Popham, F. (2018). Synthetic control methodology as a tool for evaluating population-level health interventions. *J Epidemiol Community Health, 72*(8), 673-678. doi:10.1136/jech-2017-210106

Box, G. E., Jenkins, G. M., & Reinsel, G. C. (2011). *Time Series Analysis: Forecasting and Control*: John Wiley & Sons.

Brant County Board of Health. (2018). Regular Agenda. In *Opioid Surveillance*. Brant County, ON.

Brant County Health Unit. (2017). *Annual Report 2017*. Retrieved from https://www.bchu.org/QuickLinks/Documents/BCHU_annual_report_2017edit.pdf

Brant County Health Unit. (2022). Brant/Brantford Opioid Information System. Retrieved from https://www.bchu.org/StatsAndReports/Pages/Opioid-Information.aspx

Canadian Centre on Substance Abuse, & Canadian Community Epidemiology Network on Drug Use. (2016). *CCENDU Bulletin: The Availability of Take-Home Naloxone in Canada*. Retrieved from Ottawa, ON: https://www.ccsa.ca/sites/default/files/2019-05/CCSA-CCENDU-Take-Home-Naloxone-Canada-2016-en.pdf

Canadian Institute for Health Information. (2018). *Opioid-Related Harms in Canada, December 2018*. Retrieved from Ottawa, ON: https://www.cihi.ca/sites/default/files/document/opioid-related-harms-report-2018-en-web.pdf

Canadian Institute for Health Information. (2020). *Hospital spending: Focus on the emergency department*. Retrieved from Ottawa, ON: https://www.cihi.ca/sites/default/files/document/hospital-spending-highlights-2020-en.pdf

Canadian Pharmacists Association. (2017). *Environmental Scan: Access to naloxone across Canada*. Retrieved from Ottawa, ON: https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/Environmental%20Scan%20-%20Access%20to%20Naloxone%20Across%20Canada_Final.pdf

Castanho Silva, B., & DeWitt, M. (2020). SCtools: Extensions for Synthetic Controls Analysis. R package version 0.3.1.

Caulkins, J. P., Pardo, B., & Kilmer, B. (2019). Supervised consumption sites: a nuanced assessment of the causal evidence. *Addiction, 114*(12), 2109-2115. doi:https://doi.org/10.1111/add.14747

CBC News. (2017, 8 November 2017). Toronto's first permanent supervised injection site opens downtown. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/toronto/first-permanent-safe-injection-site-1.4392720

CBC News. (2018a, 12 February 2018). Take a tour of London's Temporary Overdose Prevention Site. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/london/overdose-prevention-site-opioid-crisis-london-1.4531551

CBC News. (2018b, 21 February 2018). Toronto opens new safe injection site at Fred Victor Centre. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/toronto/safe-inection-site-fred-victor-centre-1.4544342

CBC News. (2019a, 4 October 2019). Here's what Kitchener's consumption treatment site looks like. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/kitchener-waterloo/interim-consumption-treatment-site-prepares-open-1.5307785

CBC News. (2019b, 6 November 2019). Injection site scaling back hours due to funding shortfall. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/ottawa/clarence-street-injection-site-slashes-hours-due-to-funding-shortfall-1.5349258

CBC News. (2019c, 1 November 2019). Naloxone use on the rise in Thunder Bay, health unit says. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/thunder-bay/naloxone-use-thunder-bay-1.5343182

Centre, G. C. H. (2020). Reduced Health Services Hours. Retrieved from https://guelphchc.ca/reduced-health-service-hours/

Chatham - Kent Public Health. (2017). *Annual Report 2017*. Retrieved from Chatham, ON: https://ckphu.com/wp-content/uploads/2018/12/CKPHU-Annual-Report-2017-WEB15.pdf

Chatham - Kent Public Health. (2021). Opioid Surveillance Summary. In.

City of Hamilton. (2018). Consumption and Treatment Services (CTS). Retrieved from https://www.hamilton.ca/city-initiatives/strategies-actions/consumption-and-treatment-services#:~:text=June%205%2C%202018%20Urban%20Core,Centre%20and%20Shelter%20Health%20Network.

City of Hamilton. (2022). Hamilton Opioid Information System - Naloxone. Retrieved from https://www.hamilton.ca/public-health/reporting/hamilton-opioid-information-system-naloxone

City of Toronto. (2021). Supervised Consumption Services. Retrieved from https://www.toronto.ca/community-people/health-wellness-care/health-programs-advice/supervised-injection-services/

Clementson, L. (2019). St. Catharines home to first supervised consumption site in Niagara region. Retrieved from https://www.cbc.ca/news/canada/hamilton/st-catharins-consumption-sit-1.4963875

Collins, A. B., Boyd, J., Mayer, S., Fowler, A., Kennedy, M. C., Bluthenthal, R. N., . . . McNeil, R. (2019). Policing space in the overdose crisis: A rapid ethnographic study of the impact of law enforcement practices on the effectiveness of overdose prevention sites. *International Journal of Drug Policy, 73*, 199-207. doi:https://doi.org/10.1016/j.drugpo.2019.08.002

Contenta, S. (2019). Toronto Star: Overdose prevention workers save thousands of lives, but who's saving theirs? Retrieved from https://www.srchc.ca/news/tag/ops/

Cook TD, & DT, C. (1979). *Quasi-experimentation: design analysis issues for field settings*. Boston, MA: Houghton Mifflin Company.

Crawford, B. (2018, 17 April 2018). City's first permanent supervised injection site opens at Sandy Hill Community Health Centre. *Ottawa Citizen*. Retrieved from https://ottawacitizen.com/news/local-news/citys-first-permanent-supervised-injection-site-opens-at-sandy-hill-community-health-centre

CTVNews.ca Staff. (2017). Unsanctioned pop-up safe-injection site opens in Toronto. *CTV News*. Retrieved from https://www.ctvnews.ca/canada/unsanctioned-pop-up-safe-injection-site-opens-in-toronto-1.3544860

Degli Esposti, M., Spreckelsen, T., Gasparrini, A., Wiebe, D. J., Bonander, C., Yakubovich, A. R., & Humphreys, D. K. (2020). Can synthetic controls improve causal inference in interrupted time series evaluations of public health interventions? *Int J Epidemiol, 49*(6), 2010-2020. doi:10.1093/ije/dyaa152

DelVillano, S., de Groh, M., Morrison, H., & Do, M. T. (2019). At-a-glance - Supervised Injection Services: a community-based response to the opioid crisis in the City of Ottawa, Canada. [Aperçu - Services d'injection supervisée : mesure d'intervention communautaire en réponse à la crise des opioïdes à Ottawa (Canada)]. *Health promotion and chronic disease prevention in Canada : research, policy and practice, 39*(3), 112-115. doi:10.24095/hpcdp.39.3.03

Diaczuk, D. (2018, 27 November 2018). Overdose prevention site now open. *TBnewswatch*. Retrieved from https://www.tbnewswatch.com/local-news/overdose-prevention-site-now-open-4-photos-1138000

Draaisma, M., & Lucs, I. (2020, 18 April 2020). The Works superised injection site reopens with physical distancing measures in place. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/toronto/the-works-supervised-injection-site-reopening-appointment-only-1.5537304

Fagan, L. (2019, 3 July 2019). ByWard Market supervised injeciton trailer to get permanent home. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/ottawa/supervised-injection-ottawa-trailer-1.5197477

Ferguson, E. (2018, 9 May 2018). Ministry to set up overdose prevention site. *The Kingston Whig Standard*. Retrieved from https://www.thewhig.com/2018/05/09/ministry-to-set-up-overdose-prevention-site

Foreman-Mackey, A., Bayoumi, A. M., Miskovic, M., Kolla, G., & Strike, C. (2019). 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario. *International Journal of Drug Policy, 73*, 135-140. doi:https://doi.org/10.1016/j.drugpo.2019.09.019

Fred Victor. (2020). Fred Victor's response to the COVID-19 pandemic. Retrieved from https://www.fredvictor.org/fred-victors-response-to-the-covid-19-pandemic/

Gogolishvili, D., & Wasdell, M. (2020). *Effectiveness of take-home naloxone programs and availability of naloxone nasal spray in different jurisdictions*. Retrieved from Toronto, ON: https://www.ohtn.on.ca/rapid-response-effectiveness-of-take-home-naloxone-programs-and-availability-of-naloxone-nasal-spray-in-different-jurisdictions/

Government of Canada. (2018, 03 August 2018). About the Good Samaritan Drug Overdose Act. Retrieved from https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/about-good-samaritan-drug-overdose-act.html

Government of Ontario. (2020). Ontario Demographic Quarterly: Highlights of first quarter 2020. Retrieved from https://www.ontario.ca/page/ontario-demographic-quarterly-highlights-first-quarter-2020

Griffiths, E., & Vadlamudi, N. (2016). CADTH'S $50,000 Cost-Effectiveness Threshold: Fact or Fiction? *Value Health, 19*(7), PA488-A489.

Groleau, C. (2018, 5 July 2018). Overdose prevention site in Guelph logs 430 visits since opening. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/kitchener-waterloo/guelph-overdose-prevention-site-430-visits-1.4734715

Haliburton, K., Pine Ridge District Health Unit. (2020). *2019 Annual Report: Strong Roots in our Communities*. Retrieved from Ontario: https://www.hkpr.on.ca/wp-content/uploads/2020/11/HKPR-2019-AnnualReport.pdf

Halton Region. (2021, September 2021). Opioid Reporting. Retrieved from https://www.halton.ca/For-Residents/Public-Health/Health-Statistics/Opioid-Reporting

Hamilton Public Library. (2020). Overdose Prevention Site. Retrieved from https://redbook.hpl.ca/node/14141

Hamilton Urban Core Community Health Centre. (2018). Consumption & Treatment Service. Retrieved from http://hucchc.com/health-and-wellness-programs/harm-reduction/

Harm Reduction TO. (2019). Supervised Consumption Services: OPS, SIS/SCS, & CTS. Retrieved from https://harmreductionto.ca/sis-ops-scs-cts

Hastings Prince Edward County Public Health. (2019). *The impact of opioids and other drugs in Hastings and Prince Edward Counties*. Retrieved from Belleville, ON: https://hpepublichealth.ca/wp-content/uploads/2019/11/Situational-Assessment-Opioid-and-Other-Drugs-Final.pdf

Hastings Prince Edward County Public Health. (2021). *2019 Annual Report*. Retrieved from Belleville, ON: https://hpepublichealth.ca/wp-content/uploads/2021/07/2019-Annual-report-FINAL.pdf

Hawkins, N. G., Sanson-Fisher, R. W., Shakeshaft, A., D'Este, C., & Green, L. W. (2007). The multiple baseline design for evaluating population-based research. *Am J Prev Med, 33*(2), 162-168. doi:10.1016/j.amepre.2007.03.020

Hayashi, K., Ti, L., Dong, H., Bingham, B., Day, A., Joe, R., . . . Kerr, T. (2019). Moving into an urban drug scene among people who use drugs in Vancouver, Canada: Latent class growth analysis. *PLoS One, 14*(11), e0224993. doi:10.1371/journal.pone.0224993

Health and Social Services Haldimand and Norfolk. (2018). *Health Unit Opioid Management Plan*. Retrieved from Haldimand, ON: https://hnhu.org/wp-content/uploads/HNHU-Opioid-Management-Plan.pdf

Hedlund, J. (2000). Risky business: safety regulations, risk compensation, and individual behavior. *Injury Prevention, 6*(2), 82-89. doi:10.1136/ip.6.2.82

Hurdle, L. (2019). *Consumption and Treatment Services - Street Health Centre*. Retrieved from Kingston, ON: https://www.cityofkingston.ca/documents/10180/31174463/City-Council_Meeting-03-2019_Report-19-008_Consumption-and-Treatment-Services-Street-Health-Centre.pdf/21d544db-f8ed-4a07-98cd-110fb15f3fd5

Irvine, M. A., Buxton, J. A., Otterstatter, M., Balshaw, R., Gustafson, R., Tyndall, M., . . . Coombs, D. (2018). Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. *Lancet Public Health, 3*(5), e218-e225. doi:10.1016/s2468-2667(18)30044-6

Irvine, M. A., Kuo, M., Buxton, J. A., Balshaw, R., Otterstatter, M., Macdougall, L., . . . Gilbert, M. (2019). Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. *Addiction, 114*(9), 1602-1613. doi:https://doi.org/10.1111/add.14664

Izenberg, D., Iroanyah, N., & Thompson, S. (2018). Uninsured patients in Ontario: People get sicker, the system pays more. *Healthy Debate*. Retrieved from https://healthydebate.ca/2018/07/topic/uninsured-patients-ontario/

Jones, R. P. (2018). New temporary safe injection sites open in Kensington, Regent Park. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/toronto/temporary-injection-sites-1.4639260

Jones, R. P. (2020, 17 May 2020). Injection sites scales back physical distancing rules to prevent ODs. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/ottawa/byward-market-supervised-injection-site-lifts-physical-distancing-1.5566985

Kelly, B. (2019). Overdose does not discriminate. *The Brantford Expositor*. Retrieved from https://www.brantfordexpositor.ca/news/local-news/overdose-does-not-discriminate/wcm/98f3abfa-a93c-48e0-9d3d-03367b11d2a1/amp

Kennedy, M. C., Hayashi, K., Milloy, M. J., Wood, E., & Kerr, T. (2019). Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLOS Medicine, 16*(11), e1002964. doi:10.1371/journal.pmed.1002964

Kingston Community Health Centres. (2019). *Annual Report 2017/18 Moving Upstream: Addressing the Social Determinants of Health*. Retrieved from Kingston, ON: https://kchc.ca/wp-content/uploads/2019/12/2017-2018-Annual-Report.pdf

Kingston Frontenac Lennox and Addincton Public Health. (2020). Consumption and Treatment Services. Retrieved from https://www.kflaph.ca/en/healthy-living/consumption-and-treatment-services-site.aspx

Kitching, S. (2018). Overdose Prevention Site to Open Monday. Retrieved from https://blackburnnews.com/london/london-news/2018/02/09/overdose-prevention-site-open-monday/

Kolla, G., Penn, R., & Long, C. (2019). *Evaluation of the Overdose Prevention Sites at Street Health and St. Stephen's Community House*. Retrieved from Toronto, ON: Street Health and St. Stephen's Community House

Lambton Public Health. (2019). *2018 Annual Report*. Retrieved from Lambton, ON: https://lambtonpublichealth.ca/wp-content/uploads/2019/09/2018-Annual-Report-AODA-Compliant-Compressed.pdf

Lopez Bernal, J., Cummins, S., & Gasparrini, A. (2018). The use of controls in interrupted time series studies of public health interventions. *Int J Epidemiol*. doi:10.1093/ije/dyy135

Lupton, A. (2020). COVID-19 puts new focus on space constraints at London's drug-use site. Retrieved from https://www.cbc.ca/news/canada/london/covid-19-puts-new-focus-on-space-constraints-at-london-s-drug-use-site-1.5590576

Marshall BDL, Milloy MJ, Wood E, Montaner JS, & Kerr T. (2011). Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet, 377*(9775), 1429-1437.

Medical Officer of Health. (2018). *Toronto Overdose Action Plan: Status Report 2018*. Retrieved from Toronto, ON: https://www.toronto.ca/legdocs/mmis/2018/hl/bgrd/backgroundfile-116008.pdf

Medical Officer of Health. (2019). *Toronto Overdose Action Plan: Status Report 2019*. Retrieved from Toronto, ON: https://www.toronto.ca/legdocs/mmis/2019/hl/bgrd/backgroundfile-133541.pdf

Medical Officer of Health. (2020). *Toronto Overdose Action Plan: Status Report 2020*. Retrieved from Toronto, ON: https://www.toronto.ca/legdocs/mmis/2020/hl/bgrd/backgroundfile-147549.pdf

Medical Officer of Health. (2021). *Toronto Overdose Action Plan: Status Report 2021*. Retrieved from Toronto, ON: https://www.toronto.ca/legdocs/mmis/2021/hl/bgrd/backgroundfile-167327.pdf

Middlesex-London Health Unit. (2018). Temporary Overdose Prevention Site (TOPS). Retrieved from https://www.healthunit.com/temporary-overdose-prevention-site

Middlesex-London Health Unit. (2021). Opioids - What is the situation? Retrieved from https://www.healthunit.com/opioids-middlesex-london#naloxone

Ministry of Health and Long-Term Care. (2018a). *Consumption and treatment services: Application guide*. Retrieved from Toronto, ON: https://health.gov.on.ca/en/pro/programs/opioids/docs/CTS_application_guide_en.pdf

Ministry of Health and Long-Term Care. (2018b). *Overdose Prevention Sites: User Guide for Applicants*. Retrieved from https://www.health.gov.on.ca/en/news/bulletin/2018/docs/hb_20180111_ops_user_guide.pdf

Mullin, M. (2017, 12 August 2017). Citing overdose 'crisis' police to allow unsanctioned Toronto injection site. *CBC News*. Retrieved from https://www.cbc.ca/news/canada/toronto/overdose-prevention-site-allowed-1.4245270

Municipality of Chatham-Kent. (2021). Improvements for CK Public Health's Harm Reduction Program. In *Community Human Services - Public Health Unit*. Chatham, ON.

NCHECR. (2007). *Sydney Medically Supervised Injecting Centre Evaluation Report No. 4: Evaluation of service operation and overdose-related events*. Retrieved from Sydney, NSW: https://kirby.unsw.edu.au/sites/default/files/kirby/report/EvalRep4SMSIC.pdf

News Staff. (2018). Safe injection site opens in Parkdale. *CityNews*. Retrieved from https://toronto.citynews.ca/2018/03/16/safe-injection-site-opens-in-parkdale/

Niagara Region. (2021). Naloxone use and distribution in Niagara (2019 - 2021). Retrieved from https://www.niagararegion.ca/living/health_wellness/alc-sub-abuse/drugs/opioids.aspx#topic5

Northwestern Health Unit. (2020a). *2017 Public Health Report Card*. Retrieved from https://www2.nwhu.on.ca/wp-content/uploads/2020/11/Public-Health-Report-Card-2017.pdf?x62978

Northwestern Health Unit. (2020b). *Moving Forward: 2018 Public Health Report Card*. Retrieved from https://www.nwhu.on.ca/MediaPressCentre/Documents/PHRC_2018_web.pdf

NorWest Community Health Centres. (24 March 2020). NorWest CHC is expanding its harm reduction services. Retrieved from https://www.norwestchc.org/locations/thunder-bay/programs/path-525

Ontario Agency for Health Protection and Promotion (Public Health Ontario). (2020). *Interactive Opioid Tool*. Retrieved from Toronto, ON: https://www.publichealthontario.ca/en/data-and-analysis/substance-use/interactive-opioid-tool

Ontario Association of Fire Chiefs. (2020). Analysis: Deep in the opioid crisis in Southwestern Ontario. Retrieved from https://www.oafc.on.ca/article/analysis-deep-opioid-crisis-southwestern-ontario

Ontario Ministry of Health, & Ontario Ministry of Long-Term Care. (2018). Applications Now Open for Overdose Prevention Sites. Retrieved from https://www.health.gov.on.ca/en/news/bulletin/2018/hb_20180111.aspx

Ottawa Board of Health. (2019). Subject: Next steps in harm reduction and overdose prevention. In. Ottawa, ON: Ottawa Public Health.

Ottawa Prevention. (2018). *Overdose Prevention Ottawa Summary Report*. Retrieved from Ottawa, ON: https://overdosepreventionottawa.files.wordpress.com/2018/05/overdose-prevention-ottawa-summary-report.pdf

Ottawa Public Health. (2017). Subject: Ottawa overdose prevention and response task force: Update. In. Ottawa, ON: Ottawa Public Health.

Ottawa Public Health. (2018). *2017 Annual Report*. Retrieved from Ottawa, ON: https://www.ottawapublichealth.ca/en/public-health-services/resources/Documents/oph_annual_report_2017_en.pdf

Paddon, N. (2018, 2 February 2018). Public health handing out more naloxone kits. *The Hamilton Spectator*. Retrieved from https://www.toronto.com/news-story/8107968-public-health-handing-out-more-naloxone-kits/

Panagiotoglou, D. (2022). Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series. *PLoS One, 17*(3), e0265665. doi:10.1371/journal.pone.0265665

Panagiotoglou, D., Abrahamowicz, M., Buckeridge, D. L., Caro, J. J., Latimer, E., Maheu-Giroux, M., & Strumpf, E. C. (2021). Evaluating Montréal's harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis. *BMJ Open, 11*(10), e053191. doi:10.1136/bmjopen-2021-053191

Parkdale Queen West Community Health Centre. (2018a). *Frequently Asked Questions (FAQ) about the Overdose Prevention Site at Parkdale*. Retrieved from Toronto, ON: https://pqwchc.org/wp-content/uploads/PQWCHC-FAQ_Overdose-Prevention-Services-August-16-2018.pdf

Parkdale Queen West Community Health Centre. (2018b). Hours, Location & Phone Numbers. Retrieved from https://pqwchc.org/supervised-injection-service-open-house/

Parkdale Queen West Community Health Centre. (2020). Supervised Consumption Services (SCS) - Queen West Site. Retrieved from https://pqwchc.org/programs-services/harm-reduction/supervised-consumption-services-scs/

Payne, E. (2017, 30 October 2017). Province supports new Inner City Health supervised injection site. *Ottawa Citizen*. Retrieved from https://ottawacitizen.com/news/local-news/province-supports-new-inner-city-health-supervised-injection-site

Pivot Legal Society. (2019). Canada's Supervised Consumption and Overdose Prevention Sites. Retrieved from https://www.pivotlegal.org/scs_ops_map

Pivot Legal Society. (2020). Canada's supervised consumption and overdose prevention sites. Retrieved from https://www.pivotlegal.org/scs_ops_map

Porcupine health unit. (2018). *2017 Annual Report*. Retrieved from https://www.porcupinehu.on.ca/en/your-community/reports/annual-report-mmxvii.pdf

Porcupine health unit. (2020). *Medical officer of health report to the board of health*. Retrieved from https://www.porcupinehu.on.ca/en/usermedia/reports/Medical%20Officer%20of%20Health%20Report%20to%20BOH%20-%202020-03-05.pdf

Potier C, Laprévote V, Dubois-Arber F, Cottencin O, & Rolland B. (2014). Supervised injection services: what has been demonstrated? A systematic literature review. *Drug Alcohol Depend, 1*(145), 48-68.

Pride Toronto. (2020). Community Resources in Response to COVID-19. In.

Public Health Grey Bruce. (2020). *Grey Bruce Opioid Response Plan*. Retrieved from Grey Bruce, ON: https://www.publichealthgreybruce.on.ca/Portals/0/Topics/AlcoholandDrugs/Harm%20Reduction/Grey%20Bruce%20Opioid%20Response%20Plan.pdf?ver=2020-01-23-153710-693

Public Health Grey Bruce. (2021). *Opioid Situation Report #1*. Retrieved from Grey Bruce, ON: https://www.publichealthgreybruce.on.ca/Portals/0/Topics/AlcoholandDrugs/Harm%20Reduction/Opioid_Situation_Report_Jan_to_June_2021.pdf

Public Health Ontario. (2020). *COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites*. Retrieved from Toronto, Ontario: https://www.oha.com/Bulletins/CTS%20COVID-19%20Guidance%20Document%20-%20March%2023%202020%20Shared.pdf

Public Health Sudbury District. (2021a). Naloxone Distribution. Retrieved from https://www.phsd.ca/health-topics-programs/alcohol-drugs/community-drug-strategy/research/opioid-surveillance/naloxone/

Public Health Sudbury District. (2021b). *A study to explore the need for and feasibility of implementing supervised consumption services in the City of Greater Sudbury*. Retrieved from https://www.phsd.ca/health-topics-programs/alcohol-drugs/community-drug-strategy/nafsreport/

R Core Team. (2014). R: A language and environment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing.

Raymond, T. (2018a, 6 February 2018). Ottawa Public Health to expand supervised consumption services at Clarence Street. *CTV News*. Retrieved from https://ottawa.ctvnews.ca/ottawa-public-health-to-expand-supervised-consumption-services-at-clarence-street-1.3792300

Raymond, T. (2018b, 2 May 2018). Somerset West CHC launches new supervised drug consumption site. *CTV News*. Retrieved from https://ottawa.ctvnews.ca/somerset-west-chc-launches-new-supervised-drug-consumption-site-1.3912066

Regent Park Community Health Centre. (2020). OPS Pamphlet. In R. P. C. H. Centre (Ed.). Toronto, ON.

Region of Peel. (2019). *Peel Opioid Strategy: A local response*. Retrieved from https://www.peelregion.ca/opioids/pdf/Peel-opioid-strategy.pdf

Region of Waterloo. (2018). *Waterloo Region Supervised Injection Services Feasibility Study*. Retrieved from Waterloo, ON: https://www.regionofwaterloo.ca/en/regional-government/resources/Reports-Plans--Data/Public-Health-and-Emergency-Services/SIS_Infographic.pdf

Regional Municipality of Waterloo. (2019). Harm Reduction Planning, Programs and Services Update. In (Vol. P03-20). Waterloo, ON: Region of Waterloo.

Regional Municipality of York. (2019). York Region Public Health's Opioid Action Plan. In.

Renfrew County and District Health Unit. (2018). *2017 Annual Report*. Retrieved from https://www.rcdhu.com/wp-content/uploads/2018/11/Annual-Report-2017-final-version-for-website.pdf

Renfrew County and District Health Unit. (2019). *2018 Annual Report*. Retrieved from https://www.rcdhu.com/wp-content/uploads/2019/10/Annual-Report-Draft-Sept-25-2019.pdf

Renfrew County and District Health Unit. (2020). *2019 Annual Report*. Retrieved from https://www.rcdhu.com/wp-content/uploads/2020/12/2019-RCDHU-Annual-Report-FINAL.pdf

Reynolds, C. (2021, 24 January 2021). Supervised injection sites across Canada hampered by COVID-19. *The Canadian Press*. Retrieved from https://www.cp24.com/mobile/news/supervised-injection-sites-across-canada-hampered-by-covid-19-1.5279908?cache=

Russell, C., Imtiaz, S., Ali, F., Elton-Marshall, T., & Rehm, J. (2020). 'Small communities, large oversight': The impact of recent legislative changes concerning supervised consumption services on small communities in Ontario, Canada. *Int J Drug Policy, 82*, 102822. doi:10.1016/j.drugpo.2020.102822

Scheim, A. I., Bouck, Z., Tookey, P., Hopkins, S., Sniderman, R., McLean, E., . . . Werb, D. (2021). Supervised consumption service use and recent non-fatal overdose among people who inject drugs in Toronto, Canada. *International Journal of Drug Policy, 87*, 102993. doi:https://doi.org/10.1016/j.drugpo.2020.102993

Senoran, H. (2020, 9 October 2020). Permanent CTS site coming to downtown Kitchener one year after temporary site opened. *CTV News*. Retrieved from https://kitchener.ctvnews.ca/permanent-cts-site-coming-to-downtown-kitchener-one-year-after-temporary-site-opened-1.5140182

Simcoe Muskoka District Health Unit. (2019). *2018 Status Update*. Retrieved from http://preventod.ca/Shared%20Documents/SMOS%20Status%20Update_Final2.pdf

Simcoe Muskoka District Health Unit. (2020). *Simcoe Muskoka Opioid Strategy Scorecard*. Retrieved from http://preventod.ca/Shared%20Documents/SMOS/2019%20SMOS%20SCORECARD%20DASHBOARDS%20FINAL%202020-11-02.pdf

Special Advisory Committee on the Epidemic of Opioid Overdoses. (2022). *Opioid- and Stimulant-related Harms in Canada*. Retrieved from Ottawa: Public Health Agency of Canada: https://health-infobase.canada.com/substance-related-harms/opioids-stimulants/

St. Stephen's Community House. (2018). Temporary overdose prevention site at 260 Augusta Ave. Retrieved from https://www.sschto.ca/About-Us/In-The-News/News/Overdose-Prevention-Site-at-260-Augusta-Ave

Statistics Canada. (2020). *Life tables, 2016/2018*. Retrieved from Ottawa: https://www150.statcan.gc.ca/n1/daily-quotidien/200128/dq200128a-eng.htm

Statistics Canada. (2021). *Wastewater analysis suggests that consumption of fentanyl, cannabis and methamphetamine increased in the early pandemic period*. Retrieved from Ottawa, Ontario: https://www150.statcan.gc.ca/n1/en/daily-quotidien/210726/dq210726a-eng.pdf?st=6sbuVwiK

Street Health Community Health Centre. (2018). Street Health Overdose Prevention Site. In S. Health (Ed.).

Strike, C., & Watson, T. M. (2019). Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. *International Journal of Drug Policy, 71*, 178-182. doi:https://doi.org/10.1016/j.drugpo.2019.02.005

Surveillance & Epidemiology. (2021). Toronto Overdose Information System. Retrieved from https://public.tableau.com/app/profile/tphseu/viz/TOISDashboard_Final/ParamedicResponse

Tadrous, M., Shearer, D., Martins, D., Campbell, T., & Gomes, T. (2019). *Naloxone Distribution Across Ontario*. Retrieved from Toronto, ON: https://odprn.ca/wp-content/uploads/2019/05/Naloxone-Distribution-Report-Final.pdf

Tam, T. (2018). Commentary - Building the evidence base for sustained public health response to the opioid epidemic in Canada. [Commentaire - Constituer un ensemble de données probantes au service d'une action soutenue en santé publique en réponse à la crise des opioïdes au Canada]. *Health promotion and chronic disease prevention in Canada : research, policy and practice, 38*(6), 221-222. doi:10.24095/hpcdp.38.6.01

The Corporation of the City of Sault Ste. Marie. (2019). Council Correspondence. In. Sault Ste. Maria, ON: City of Sault Ste. Marie.

The Evaluation of Overdose Prevention Sites Working Group, & Lori Wagar. (2018). *Evaluation of Overdose Prevention Sites: Campbell River, Courtenay, Cowichan Valley, and Port Alberni - FINAL REPORT*. Retrieved from Victoria, BC: https://www.islandhealth.ca/sites/default/files/2018-10/evaluation-OPS-report.pdf

The Sault Star. (2019, 4 May 2019). News briefs. *The Sault Star*. Retrieved from https://www.saultstar.com/news/local-news/news-briefs-14/wcm/e7ef6eab-d7c9-4cfd-a055-5f2b72a78a4c/amp/

The Welland Tribune. (2020). Positive living Niagara facing challenges during pandemic. *Niagara Falls Review*. Retrieved from https://www.niagarafallsreview.ca/news/niagara-region/2020/04/13/positive-living-niagara-facing-challenges-during-pandemic.html

Thunder Bay District Health Unit. (2022). Opioid Information System. Retrieved from https://www.tbdhu.com/opioidinfo

Toronto Central Health Line. (2021a). Parkdale Queen West Community Health Centre - Parkdale Site. Retrieved from https://www.torontocentralhealthline.ca/displayservice.aspx?id=167074

Toronto Central Health Line. (2021b). Queen and Jarvis Site - Supervised Consumption Service. Retrieved from https://www.torontocentralhealthline.ca/displayservice.aspx?id=182489

Toronto Drop-In Network. (2018). Overdose Prevention Site, Supervised Injection Services and Safe Consumption Service Hours List. In. Toronto, ON.

Toronto Drop-In Network. (2020). Evaluation of the Overdose Prevention Services at St. Stephen's Community House and Street Health. Retrieved from https://www.tdin.ca/resource.php?id=671

Toronto Public Health. (2020). @TOPublicHealth. Retrieved from https://twitter.com/topublichealth/status/1259885006396284929

Toronto Public Health. (2022). Toronto Overdose Information System. Retrieved from https://public.tableau.com/app/profile/tphseu/viz/TOISDashboard_Final/ParamedicResponse

VanderWeele, T. J., & Shpitser, I. (2011). A new criterion for confounder selection. *Biometrics, 67*(4), 1406-1413. doi:10.1111/j.1541-0420.2011.01619.x

Wellington-Dufferin-Guelph, P. H. (2019). Naloxone Distribution Program. In.

Wellington-Duffering-Guelph, P. H. (2018). Where to get take-home naloxone kits. Retrieved from https://www.wdgpublichealth.ca/your-health/opioids-and-naloxone/local-opioid-resources

Whan, C. (2018, 2 May 2018). New temporary overdose prevention site opens in Somerset West. *Global News*. Retrieved from https://globalnews.ca/news/4181806/new-temporary-overdose-prevention-site-opens-in-somerset-west/

Windsor-Essex County Health Unit. (2021). Opioid Overdose Statistics. Retrieved from https://www.wechu.org/reports/opioid-overdose-statistics

Zhang F, Wagner AK, & Ross-Degnan D. (2011). Simulation-based power calculation for designing interrupted time series analyses of health policy interventions. *J Clin Epidemiol, 64*(11), 1252-1261.